Clinical trial NCT02584660
Conditions: Pulmonary Embolism
Keywords: Rivaroxaban JNJ39039039 Pulmonary embolism
Sponsor: Janssen Scientific Affairs, LLC
Start date: 2015-10-15; Completion date: 2017-03-22
Enrollment: 114 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of the study is to evaluate that low risk Pulmonary Embolism (PE) participants who are discharged from the Emergency Department (ED) to the home environment and treated with rivaroxaban as outpatients have fewer total days in the hospital for bleeding and/or venous thromboembolism (VTE) events through Day 30 compared to participants who are treated with initial hospitalization and standard-of-care.

Detailed description:
This is a randomized (study medication is assigned by chance), open-label (all people know the identity of the intervention), parallel-group, multicenter (study conducted at multiple sites) study to evaluate that low risk PE participants who are discharged from the ED and treated with rivaroxaban compared to participants who are treated with initial hospitalization and standard-of-care. The study consists of a Screening and Randomization Period, followed by a 90-day open-label treatment period, and an end of study/early withdrawal (EOS) visit. The duration of study participation for each participant is approximately 3 months. The participants will be randomized in a 1:1 ratio to one of two treatments. Safety will be monitored during the study.

Arms: arm 1: Participants will receive Rivaroxaban 15 milligram (mg) orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food, for approximately 69 days for a total treatment duration of 90 days. arm 2: Participants will receive local Standard-of-care as per local protocol and defined by the medical team caring for the participant.
Interventions: intervention 1: Rivaroxaban intervention 2: Standard-of-care
Intervention descriptions: intervention 1: Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally. intervention 2: Standard-of-care as per local protocol and defined by the medical team caring for the participant.

Protocol documents:
Prot_000.pdf: 
1
Status: Approved,  Date: 16 June 2015
Janssen Scientific Affairs, LLC *
Clinical Protocol
MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the 
Emergency Department (MERCURY PE)
Protocol 39039039APE4001; Phase 4
JNJ-39039039; BAY 59-7939  (rivaroxaban)
* Rivaroxaban (JNJ-39039039, BAY-59-7939) is being codeveloped under a collaboration and license
agreement between Bayer HealthCare AG (BHC) and Ortho McNeil Pharmaceuticals, Inc (OMP) dated
October 1, 2005. As determined by the parties, both BHC and Janssen Pharmaceuticals Inc (successor in
interest to OMP) may use affiliated corporate entities to conduct this clinical trial. With regard to Janssen
Pharmaceuticals Inc, such affiliates may include Janssen Research & Development, LLC (formerly
Johnson & Johnson Pharmaceutical Research & Development LLC), Janssen Scientific Affairs, LLC, and
Janssen-Cilag International NV. The term "sponsor" or "designee" is used throughout the protocol to
represent these various legal entities that have been identified to perform various clinical trial services;
the actual sponsor or designee is identified on the Contact Information page that accompanies this
protocol.
This compound is approved for marketing in 6 indications in the United States.
Status:
Approved
Date:
16 June 2015
Prepared by:
Janssen Scientific Affairs, LLC
EDMS number:
EDMS-ERI-102610147
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or 
confidential.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
2
Approved, Date: 16 June 2015
TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF ATTACHMENTS............................................................................................................................ 4
LIST OF IN-TEXT TABLES AND FIGURES................................................................................................ 4
SYNOPSIS.................................................................................................................................................... 5
TIME AND EVENTS SCHEDULE ................................................................................................................ 9
ABBREVIATIONS ...................................................................................................................................... 11
1.
INTRODUCTION................................................................................................................................ 12
1.1.
Background .................................................................................................................................... 12
1.1.1.
Compound Profile....................................................................................................................... 13
1.1.2.
Efficacy and Safety Profile Based on Clinical Studies................................................................ 13
1.2.
Overall Rationale for the Study...................................................................................................... 15
2.
OBJECTIVES AND HYPOTHESIS ................................................................................................... 17
2.1.
Objectives ...................................................................................................................................... 17
2.2.
Hypothesis ..................................................................................................................................... 18
3.
STUDY DESIGN AND RATIONALE ................................................................................................. 18
3.1.
Overview of Study Design.............................................................................................................. 18
3.2.
Study Design Rationale.................................................................................................................. 19
4.
SUBJECT POPULATION.................................................................................................................. 22
4.1.
Inclusion Criteria ............................................................................................................................ 22
4.2.
Exclusion Criteria ........................................................................................................................... 24
4.3.
Prohibitions and Restrictions ......................................................................................................... 26
5.
TREATMENT ALLOCATION AND BLINDING................................................................................. 26
6.
DOSAGE AND ADMINISTRATION .................................................................................................. 27
6.1.
Temporary Discontinuation of Study Drug..................................................................................... 28
7.
TREATMENT COMPLIANCE............................................................................................................ 28
8.
PRESTUDY AND CONCOMITANT THERAPY ................................................................................ 29
9.
STUDY EVALUATIONS .................................................................................................................... 30
9.1.
Study Procedures........................................................................................................................... 30
9.1.1.
Overview..................................................................................................................................... 30
9.1.2.
Screening Phase ........................................................................................................................ 30
9.1.3.
Open-Label Treatment Phase .................................................................................................... 30
9.2.
Efficacy........................................................................................................................................... 31
9.2.1.
Evaluations ................................................................................................................................. 31
9.2.2.
Endpoints.................................................................................................................................... 32
9.3.
Biomarkers ..................................................................................................................................... 33
9.4.
Patient-Reported Outcomes .......................................................................................................... 33
9.5.
Safety Evaluations ......................................................................................................................... 34
9.5.1.
Bleeding Events.......................................................................................................................... 34
9.5.2.
Other Safety Assessments ......................................................................................................... 35
9.6.
Sample Collection and Handling.................................................................................................... 36
10.
SUBJECT COMPLETION/WITHDRAWAL....................................................................................... 37
10.1.
Completion ..................................................................................................................................... 37
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
3
Approved, Date: 16 June 2015
10.2.
Withdrawal From the Study............................................................................................................ 37
11.
STATISTICAL METHODS................................................................................................................. 38
11.1.
Subject Information ........................................................................................................................ 38
11.2.
Sample Size Determination ........................................................................................................... 38
11.3.
Analyses for Primary and Secondary Endpoints ........................................................................... 39
11.4.
Safety Analyses ............................................................................................................................. 39
11.5.
Committees .................................................................................................................................... 41
11.5.1.
Executive Committee.................................................................................................................. 41
11.5.2.
Clinical Endpoint Committee....................................................................................................... 41
11.5.3.
Data Monitoring Committee........................................................................................................ 41
11.5.4.
Study Coordinator Operational Committee................................................................................. 41
12.
ADVERSE EVENT REPORTING ...................................................................................................... 41
12.1.
Definitions ...................................................................................................................................... 42
12.1.1.
Adverse Event Definitions and Classifications ........................................................................... 42
12.1.2.
Attribution Definitions.................................................................................................................. 43
12.1.3.
Severity Criteria .......................................................................................................................... 44
12.2.
Special Reporting Situations.......................................................................................................... 44
12.3.
Procedures..................................................................................................................................... 45
12.3.1.
All Adverse Events...................................................................................................................... 45
12.3.2.
Serious Adverse Events ............................................................................................................. 46
12.3.3.
Pregnancy................................................................................................................................... 47
12.4.
Contacting Sponsor Regarding Safety........................................................................................... 47
13.
PRODUCT QUALITY COMPLAINT HANDLING.............................................................................. 48
13.1.
Procedures..................................................................................................................................... 48
13.2.
Contacting Sponsor Regarding Product Quality ............................................................................ 48
14.
STUDY DRUG INFORMATION......................................................................................................... 48
14.1.
Physical Description of Study Drug(s) ........................................................................................... 48
14.2.
Packaging ...................................................................................................................................... 48
14.3.
Labeling.......................................................................................................................................... 48
14.4.
Preparation, Handling, and Storage............................................................................................... 49
14.5.
Drug Accountability ........................................................................................................................ 49
15.
STUDY-SPECIFIC MATERIALS....................................................................................................... 49
16.
ETHICAL ASPECTS ......................................................................................................................... 50
16.1.
Study-Specific Design Considerations........................................................................................... 50
16.2.
Regulatory Ethics Compliance....................................................................................................... 50
16.2.1.
Investigator Responsibilities ....................................................................................................... 50
16.2.2.
Independent Ethics Committee or Institutional Review Board ................................................... 50
16.2.3.
Informed Consent ....................................................................................................................... 52
16.2.4.
Privacy of Personal Data ............................................................................................................ 52
16.2.5.
Long-Term Retention of Samples for Additional Future Research ............................................ 53
17.
ADMINISTRATIVE REQUIREMENTS .............................................................................................. 53
17.1.
Regulatory Documentation ............................................................................................................ 53
17.1.1.
Regulatory Approval/Notification ................................................................................................ 53
17.1.2.
Required Prestudy Documentation............................................................................................. 54
17.2.
Protocol Amendments.................................................................................................................... 54
17.3.
Subject Identification, Enrollment, and Screening Logs ................................................................ 55
17.4.
Source Documentation................................................................................................................... 55
17.5.
Case Report Form Completion ...................................................................................................... 56
17.6.
Data Quality Assurance/Quality Control ........................................................................................ 57
17.7.
Record Retention ........................................................................................................................... 57
17.8.
Monitoring ...................................................................................................................................... 58
17.9.
Study Completion/Termination....................................................................................................... 58
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
4
Approved, Date: 16 June 2015
17.9.1.
Study Completion ....................................................................................................................... 58
17.9.2.
Study Termination....................................................................................................................... 58
17.10.
On-Site Audits ................................................................................................................................ 59
17.11.
Use of Information and Publication................................................................................................ 59
REFERENCES............................................................................................................................................ 61
INVESTIGATOR AGREEMENT ................................................................................................................. 69
LAST PAGE................................................................................................................................................ 69
LIST OF ATTACHMENTS
Attachment 1
Reporting of Study Endpoints, Adverse Drug Reactions, Adverse Events and 
Serious Adverse Events ............................................................................................. 63
Attachment 2
Switching to or From Rivaroxaban ............................................................................. 64
Attachment 3
Anti-Clot Treatment Scale (ACTS) Questionnaire...................................................... 65
Attachment 4
Site-of-Care Satisfaction Questionnaire..................................................................... 67
Attachment 5
Cockcroft and Gault formulas..................................................................................... 68
LIST OF IN-TEXT TABLES AND FIGURES 
TABLES
Table 1
Hestia Exclusion Criteria for Outpatient Treatment .................................................................. 15
Table 2
Original and Simplified Pulmonary Embolism Severity Index (PESI) ....................................... 16
FIGURES
Figure 1:
Study Diagram: Clinical Protocol 39039039APE4001.............................................................. 19
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
5
Approved, Date: 16 June 2015
SYNOPSIS
MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency 
Department (MERCURY PE)
Rivaroxaban (JNJ-39039039; BAY 59-7939) is an oral anticoagulant. The mechanism of action of 
rivaroxaban is to selectively and to directly inhibit Factor Xa, which plays a central role in the cascade of 
blood coagulation by mediating thrombin formation. Rivaroxaban does not require metabolic conversion 
or a cofactor to exert its activity.
Rivaroxaban is marketed under the trade name XARELTO® and has been approved for multiple 
indications worldwide, including deep vein thrombosis (DVT) and pulmonary embolism (PE). In recent 
years, the ability to rapidly and to accurately stratify patients with PE according to their risk of clinical 
deterioration has gained importance and there is evidence that patients at low risk of clinical deterioration 
may be eligible for outpatient treatment with oral anticoagulants. The primary objective of this study is to 
determine if patients diagnosed with PE and identified as being at low risk of clinical deterioration may 
be safely discharged from the Emergency Department (ED) and treated with rivaroxaban as outpatients. 
OBJECTIVE AND HYPOTHESIS
Primary Objective
The primary objective of the study is to demonstrate that low risk PE patients who are discharged from 
the ED to the home environment and treated with rivaroxaban as outpatients have fewer total days in the 
hospital for bleeding and/or venous thromboembolism (VTE) events through Day 30 compared to patients 
who are treated with initial hospitalization and standard-of-care. 
Secondary Objective
The secondary objective of the study is to assess the reoccurrence of symptomatic, objectively confirmed 
VTE, defined as recurrent PE or new or recurrent DVT (including symptomatic upper extremity DVT) or 
VTE related death within 90 days of randomization.
Exploratory Objective
The exploratory objective of this study is to evaluate patient outcomes by baseline risk factors
Hypothesis
Clinical: 
The clinical hypothesis is that an early discharge strategy for low risk PE patients, identified in the ED, 
and discharged to the home environment and treated with rivaroxaban as outpatients will result in fewer 
days in the hospital for bleeding and/or VTE events through Day 30 than patients treated with 
standard-of-care. 
Safety:
The safety hypothesis is that major bleeding rates as assessed by the International Society on Thrombosis 
and Haemostasis (ISTH) criteria at 90 days of randomized treatment will be similar between the 
rivaroxaban and standard-of-care strategies.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
6
Approved, Date: 16 June 2015
OVERVIEW OF STUDY DESIGN
This is a randomized, open-label, parallel-group, multicenter study conducted in the United States (US). 
Eligible subjects will include men and women, 18 years of age and older, who have a confirmed diagnosis 
of acute symptomatic PE with or without symptomatic DVT. Approximately 300 PE subjects presenting 
to the ED and assessed as being at low risk of clinical deterioration using the Hestia criteria will be 
randomized in a 1:1 ratio to one of two treatment strategies: 1) rivaroxaban and discharge from the ED to 
the home environment or 2) standard-of-care (as per local protocol and defined by the medical team 
caring for the subject). All subjects will be followed for 90 days after starting randomized treatment. 
Subjects meeting all inclusion and no exclusion criteria will be eligible for enrollment.
The Hestia criteria are predefined validated clinical criteria that can be used to identify subjects with PE 
who are at low risk for subsequent clinical deterioration and who are candidates for anticoagulant
treatment on an outpatient basis.  
The study consists of a Screening and Randomization Period, followed by a 90-day open-label treatment 
period, and an end-of-study/early withdrawal (EOS) visit.  The duration of study participation for each 
subject is approximately 3 months. 
Subjects will undergo screening in the ED and must be randomized within 12 hours after the confirmation 
of PE diagnosis. All bleeding events (ISTH major and clinically relevant non-major bleeding events),
efficacy events (VTE related death, recurrence of PE or new or recurrent DVT) and all deaths during the 
study will be adjudicated in a blinded manner by a Clinical Endpoints Committee (CEC).  Events will be 
adjudicated throughout the entire 90 days of randomized treatment. The CEC will independently review 
clinical events data as they become available, and will adjudicate and will classify deaths, bleeding 
events, and recurrence of PE and new or recurrent DVT in a consistent and unbiased manner.
An independent Data Monitoring Committee (DMC) will monitor the progress of the study and will
ensure the safety of study subjects. An Executive Committee will be established and will review
recommendations from the DMC regarding safety analyses and/or study modifications and will oversee 
implementation, if necessary, of these study modifications. In addition a Study Coordinator Operational 
Committee will be established to provide input to the operational logistics regarding study design and 
conduct of the study.
The frequency and timing of efficacy, safety, and other measurements are provided in the Time and 
Events Schedule.
SUBJECT POPULATION
Eligible subjects are men or women, 18 years of age or older, who present to the ED and have a 
confirmed diagnosis of an acute symptomatic PE with or without symptomatic DVT and who are deemed 
to be at low risk of clinical deterioration as determined by the Hestia criteria. PE diagnosis is expected to 
be confirmed per local standard-of-care with imaging techniques such as Computed Tomography,
Pulmonary Angiography or Pulmonary Ventilation/Perfusion scan.
DOSAGE AND ADMINISTRATION
Subjects will be randomly assigned to 1 of 2 treatment strategies in a 1:1 ratio:

Rivaroxaban at an initial dose of 15 mg taken orally twice daily with food for the first 21 days
followed by a dose of 20 mg taken orally once daily with food, at approximately the same time each 
day for approximately 69 days for a total treatment duration of 90 days.
OR

Standard-of-care (per local protocol and defined by the medical team caring for the subject)
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
7
Approved, Date: 16 June 2015
Missed Dose
If a dose of rivaroxaban is not taken at the scheduled time, administer the dose as soon as possible on the 
same day as follows:

For subjects receiving 15 mg twice daily: The subject should take rivaroxaban immediately to ensure 
intake of 30 mg rivaroxaban per day. In this instance, two 15 mg tablets may be taken at once. The 
subject should continue with the 15 mg twice daily regimen on the following day.

For subjects receiving 20 mg once daily: The subject should take the missed rivaroxaban dose
immediately.
EFFICACY EVALUATIONS/ENDPOINTS
Primary Endpoint
The primary clinical endpoint is the number of days of initial inpatient hospitalization (beginning from 
randomization to discharge from the hospital) plus any subsequent hospitalization(s) related to bleeding 
and/or VTE events up to 30 days.
Secondary Endpoints

Reoccurrence of symptomatic, objectively confirmed VTE, defined as recurrent PE or new or 
recurrent DVT (including symptomatic upper extremity DVT) or VTE related death within 90 days 
of randomization.

Number of unplanned hospital or physician office visits for VTE symptoms and/or bleeding through 
90 days.

Length of initial and subsequent hospitalization(s) for any reason through Day 90.

Patient-reported outcomes will be captured at Day 7 for Site-of-Care Satisfaction and on Days 14,
30, and 90 for Anti-Clot Treatment Scale.

Length of initial and subsequent hospitalizations as well as, VTE related re-hospitalization(s) due to 
recurrence will be economically evaluated.
EXPLORATORY EVALUATIONS
Outcomes by baseline risk factors will be evaluated.
BIOMARKER EVALUATIONS
A blood sample for biomarkers will be collected at screening from all subjects who give their consent for 
this blood sample. Biomarker samples will be used for research related to rivaroxaban, analysis of 
molecules involved in the clotting pathway, study comedications, and/or PE. They may also be used to 
develop tests/assays related to rivaroxaban, study comedications, or PE. 
Patient-Reported Outcomes
Treatment and Site-of-Care satisfaction will be assessed. At follow-up visits Day 14, Day 30, and Day 90 
treatment satisfaction will be assessed using a validated measure for treatment satisfaction: the ACTS. 
The Satisfaction to Site-of-Care questionnaire (standard-of-care versus early discharge on rivaroxaban 
therapy) will be administered after 7 days on anticoagulant therapy.
The ACTS is comprised of two 2 subscales: Burdens (12 items) and Benefits (3 items). The treatment 
experience scores range from ‘Not at all’ to ‘Extremely’ on a five-point Likert scale (psychometric 
rating); higher scores indicate greater satisfaction with treatment.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
8
Approved, Date: 16 June 2015
Satisfaction to Site-of-Care (hospitalization versus home care) rates the patient’s level of satisfaction to 
care and location with care received as well as preference to location of care provided.  Patients rate the 
three 3 items of this scale of 1=Very satisfied; 2=Quite satisfied; 3=Neither; 4=Quite dissatisfied; and 
5=Very dissatisfied for satisfaction questions and for the one preference question responses include 1=In 
the hospital; 2=In the community; and 3=No preference. This satisfaction scale will be administered after 
one 1 week on anticoagulant therapy. Statistical testing generating p values will be calculated for 
comparisons of hospital care and home care. 
Medical Resource Utilization and Health Economics
Medical resource utilization and health economics data, associated with medical encounters, will be 
collected in the eCRF by the investigator and study-site personnel for all subjects throughout the study. 
Length of initial and subsequent hospitalizations as well as, all-cause and VTE related re-hospitalizations 
due to recurrence will be economically evaluated.
SAFETY EVALUATIONS/ENDPOINTS 
Safety Evaluations
All bleeding events will be captured as an Adverse Event of special interest.

Primary safety:  ISTH major bleeding

Secondary safety: Clinically relevant non-major bleeding
Primary Safety Endpoint
The primary safety endpoint is ISTH major bleeding at Day 90.
Secondary Safety Endpoints
The secondary safety endpoints are VTE related death within 90 days of randomization and overall safety 
defined as a composite of ISTH major bleeding, clinically relevant non-major bleeding, and mortality.
STATISTICAL METHODS
Following pragmatic considerations, the sample size for this study was determined using assumptions 
related to the expected number of days of initial inpatient hospitalization (beginning from randomization 
to discharge from the hospital) and any subsequent hospitalization(s) related to bleeding and/or VTE 
events up to 30 days. A large-sample confidence interval (CI) approach was used to determine the sample 
size required for estimating the difference in mean length of stay between the two randomized groups. 
From Aujesky et al. 2011; the standard deviation is 1 day for the outpatient group and 3.1 days for the
inpatient group from the initial hospital stay. From the available data, the average number of days of 
hospitalization after discharge is less than 2 days and the percentage of patients with VTE related 
hospitalization is less than 5%. With this information, the contribution from VTE related hospitalization 
after discharge has a very small impact on the standard deviations received from the initial hospital stays 
which were used in the sample size calculation. A total of a 150 subjects per group will provide a 
two-sided 95% CI with about a 0.5 day of margin of error.  The margin of error is defined as the quantity 
from the observed difference in means to the end point of the CI. 
The above sample size estimate will also allow an examination of the difference in the recurrence of VTE 
events in the 2 randomized groups. The incidence of recurrent VTE events is generally low and largely 
infrequent among low-risk PE patients. In the Aujesky et al. 2011 study, the 90-day recurrence rates of 
VTE among both inpatients and outpatients were reported to be less than 1% (with a 95% upper 
confidence limit = 2.7%).
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
9
Approved, Date: 16 June 2015
TIME AND EVENTS SCHEDULE 
  Phase
Period
Visit 1
Screening and Randomizationa
Phone call 
Follow up #1
Phone call 
Follow up 
#2
Phone call 
Follow up #3
Visit 2
End of 
Study/Early 
Termination 
Visit 3b
Day
0/1
3 (± 1 day)
7 (± 2 days)
14 (± 2 days)
30 (-5) 
days
90 ± 5 days
Study Procedure
Screening/Administrative
PE Diagnosis/confirmationc
X
Informed consent (ICF)
X
Inclusion/exclusion criteria
X
Medical history and demographics
X
ED anticoagulant therapy (if applicable)
Xd
Pregnancy test
Xe
Physical examinationf
X
Vital signsg
X
12-lead ECGh
X
Height and Weight
X
Study Drug Administration
Randomization
X
Dispensation/administration of study drug
X
X
Drug accountabilityi
X
X
X
X
X
Safety Assessments
ISTH major bleeding
X
X
X
X
X
X
Clinically relevant non-major bleeding events
X
X
X
X
X
X
Clinical Events
VTE related death
X
X
X
X
X
X
Recurrence of PE or new or recurrent DVT
X
X
X
X
X
X
PRO Assessments
ACTSj.
X
X
X
Satisfaction to Site-of-Carek
X
Clinical Laboratory Assessments (Blood samples)
CrCll
X
Troponin
X
Biomarker samplem
X
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
10
Approved, Date: 16 June 2015
  Phase
Period
Visit 1
Screening and Randomizationa
Phone call 
Follow up #1
Phone call 
Follow up 
#2
Phone call 
Follow up #3
Visit 2
End of 
Study/Early 
Termination 
Visit 3b
Day
0/1
3 (± 1 day)
7 (± 2 days)
14 (± 2 days)
30 (-5) 
days
90 ± 5 days
Study Procedure
Ongoing Subject Review
Concomitant therapyn
X
X
X
X
X
X
Adverse events
X
X
X
X
X
X
a)
Subjects must be randomized within 12 hours after confirmation of PE diagnosis in the ED
b)
The end of study visit will be performed at one of the following timepoints: at the completion of the open-label treatment with study drug Day 90 (± 5 days), or 
as soon as possible after a subject permanently discontinues study drug. For subjects who discontinue study drug prior to Day 90 (± 5 days), the site should 
make every effort to complete final study assessments. At a minimum, a final vital status (dead/alive) either by telephone or in person, or if applicable, by a 
review of the subject’s medical record or available public records, unless this contact is not allowed by local regulation should be completed for all subjects 
who discontinue study drug prior to Day 90 (± 5 days). 
c)
PE diagnosis is expected to be confirmed per local standard-of-care with imaging techniques such as Computed Tomography, Pulmonary Angiography or V/Q 
scan.
d)
A previous dose of VKA and or LMWH/UFH is allowed prior to randomization and must be recorded in the eCRF.
e)
Women of childbearing potential must have a negative urine pregnancy test done locally at screening. Serum pregnancy testing may be performed if required 
by local regulation. Additional serum or urine pregnancy tests may be performed, as determined necessary by the investigator or required by local 
regulation, to establish the absence of pregnancy at any time during the subject's participation in the study.
f)
The extent of the physical examination should be conducted by the site per usual local standard-of-care.
g)
Vital signs include temperature, pulse/heart rate, respiratory rate, and blood pressure. 
h)
If blood sampling or vital sign measurement is scheduled for the same time point as electrocardiogram (ECG) recording, the procedures should be performed in 
the following order: ECG(s), vital signs, and blood draw.
i)
Returned sponsor-supplied rivaroxaban will be counted at the in-person visits. Telephone calls should include a question regarding subject compliance with 
study drug.
j)
The site will administer the ACTS by phone at Day 14(±2 days) ,and in person at the site at Day 30 (-5 days) and Day 90 (±5 days).
k)
The site will administer the Satisfaction to Site-of-Care (hospitalization versus home care) questionnaire by phone at Day 7 of anticoagulant therapy (± 2 days).
l)
CrCl to be conducted by the local laboratory using the Cockroft Gault formula using actual body weight. See Attachment 5
m)
For all subjects who provide their consent for this sample an optional biomarker sample will be collected.
n)
All medications, prescription and over the counter, including vitamins used within 14 days of the first dose of study drug and throughout the open-label 
treatment period of study drug must be recorded in the eCRF.
PE= pulmonary embolism; ICF= informed consent form; ED= emergency department; ECG= electrocardiogram; ISTH= International Society of Thrombosis and 
Haemostasis; V/Q= Pulmonary Ventilation/Perfusion ; VTE= venous thromboembolism; DVT= deep vein thrombosis; ACTS= Anti-Clot Treatment Scale; CrCl= 
serum creatinine; VKA= vitamin K antagonist; LMWH= low molecular weight heparin; UFH= unfractionated heparin; eCRF= electronic case report form.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
11
Approved, Date: 16 June 2015
ABBREVIATIONS
AE
ACTS
Adverse Event
Anti-Clot Treatment Scale
CEC
eCRF
CT
Clinical Endpoints Committee
electronic case report form 
Computed Tomography
DMC
DVT
EC
Data Monitoring Committee
deep vein thrombosis
Executive Committee
ED
Emergency Department
ECG
electrocardiogram
EOS
end of study/early withdrawal
FXa
Factor Xa
eDC
electronic data capture
GCP
Good Clinical Practice
ICF
informed consent form
ICH
International Conference on Harmonisation
IEC
Independent Ethics Committee
INR
IRB
International Normalized Ratio
Institutional Review Board
ISTH
International Society on Thrombosis & Haemostasis
LMWH
low molecular weight heparin
LOS
length of stay
NHAMCS
National Hospital Ambulatory Medical Care Survey
PE
pulmonary embolism
PESI
Pulmonary Embolism Severity Index
PQC
Product Quality Complaint
PRO
SC OC
patient-reported outcome(s)
Study Coordinator Operational Committee
UFH
unfractionated heparin
US
United States
VKA
vitamin K antagonists
VTE
venous thromboembolism
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
12
Approved, Date: 16 June 2015
1.
INTRODUCTION
Rivaroxaban (JNJ-39039039; BAY 59-7939) is an oral, direct acting, Factor Xa (FXa) inhibitor 
anticoagulant that has been under development for the treatment of several thrombosis-mediated 
conditions. Rivaroxaban is marketed under the trade name XARELTO® and has been approved 
for multiple indications worldwide. The clinical development program for rivaroxaban is 
extensive. As of 15 September 2014, over 84,000 subjects have been enrolled in interventional 
trials from Phase 1 through multiple large Phase 4 studies covering several indications and 
potential indications. Over 47,000 of these subjects have been exposed to rivaroxaban in 
completed and ongoing company-sponsored interventional clinical trials and non-interventional 
studies, with the total daily doses of rivaroxaban ranging between 5 mg and 60 mg.
For the most comprehensive nonclinical and clinical information regarding rivaroxaban, refer to 
the latest version of the Investigator's Brochure and Addenda for rivaroxaban.14
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
1.1.
Background
Hemostasis is a normal physiological process following damage of the vascular system. In 
various diseases, however, the hemostatic mechanisms are inappropriately activated with
pathological consequences causing thrombosis. Venous thromboembolism (VTE) including deep 
vein thrombosis (DVT) and pulmonary embolism (PE), represents one of the most common
health problems in the United States (US). It is estimated that more than 2 million Americans 
develop an acute VTE event each year. In the European Union, incidence rates of DVT and PE 
are assumed to be slightly higher, but are generally consistent with those in the US. 10,27
Deep vein thrombosis and PE are a burden for healthcare systems. They are associated with the 
potential for mortality and considerable morbidity in terms of recurrent events, post-thrombotic 
syndrome, and chronic thromboembolic pulmonary hypertension.12,21,32 The treatment of DVT 
and PE aims at prevention of worsening of the existing thrombus, as well as prevention of 
recurrence of VTE31 by the use of anticoagulants.
Historically, the only available oral anticoagulant was warfarin, an oral vitamin K antagonist
(VKA). When first initiated, warfarin required 4 to 5 days to become effective and initial 
outpatient management was not possible as there would be an initial period where, despite proper 
warfarin dosing, there would be no functional anticoagulation. Therefore, for all patients 
requiring acute anticoagulation (eg, all new VTE diagnoses), hospitalization for intravenous 
anticoagulation bridging, until warfarin became effective, was the only option available. With 
the advent and availability of subcutaneously administered low molecular weight heparin 
(LMWH), a new option for bridging until warfarin became effective was possible. Theoretically, 
since intravenous therapy was no longer required, patients could avoid hospitalization by the 
self-injection of LMWH. Unfortunately, because of a lack of educational resources, a negative 
reimbursement structure, and general patient resistance to self-injection, the use of LMWH to 
avoid initial hospitalization for VTE therapy was generally poorly adopted in the US.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
13
Approved, Date: 16 June 2015
PE is a common diagnosis in the Emergency Department (ED); it is estimated that approximately 
142,000 ED patients are diagnosed annually.13 The risk of mortality and other serious side effects 
secondary to PE differs greatly according to underlying risk factors. While patients presenting 
with shock may experience a short-term mortality in excess of 30%17,25 patients assessed to be at 
low risk have a reported mortality of less than 1%.1,33 Patients with PE deemed to be at low risk
are typically defined as patients who are hemodynamically stable without hypoxia, have no 
evidence of right heart strain or myocardial necrosis as evidenced by a normal troponin, and have 
a low risk of short-term mortality of less than 1%.1,26,33 If anticoagulation bridging was 
unnecessary, this latter cohort could be potential candidates for outpatient treatment.
The advantages of avoiding hospitalization by outpatient treatment are numerous. Unnecessary 
hospitalization in and of itself represents an avoidable risk of adverse events.
Not only is there an advantage to avoiding hospitalization, but also the costs of a several day 
admission is significant. It is estimated that the average cost of a single inpatient PE therapy visit 
is $14,000.9 Multiplied by the annual 142,000 ED PE diagnoses this equates to nearly 2 billion in 
expenditures.7 It should be obvious that a large savings could be realized if an outpatient 
management strategy was used in only a very small percentage of selected PE patients.
Previous studies with LMWH and VKA have suggested that patients with PE who are at low risk 
of adverse events may be safely and effectively treated with anticoagulation therapy on an 
outpatient basis instead of being admitted to the hospital.1,4,33 A recent systematic review and 
meta-analysis suggests that outpatient management of low risk PE is both feasible and safe as 
measured by low event rates at both 14 days and 3 months of follow up.22
1.1.1.
Compound Profile
Rivaroxaban is an oral, direct, FXa inhibitor anticoagulant. Rivaroxaban is rapidly absorbed after 
oral administration, with peak plasma concentrations occurring approximately 2- to 4-hour 
postdose. The elimination pathways of rivaroxaban include both hepatic and renal routes. The 
terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy young subjects and from 
11 to 13 hours in healthy elderly subjects (aged 65 to 83 years). Due to the multiple elimination 
pathways of rivaroxaban, there are few clinically relevant drug-drug interactions.
Rivaroxaban has been under development and is approved for the treatment of several 
thrombosis mediated conditions. The clinical development program for rivaroxaban is extensive 
with over 84,000 subjects having been studied in interventional trials from Phase 1 through 
multiple large Phase 4 studies covering several indications and potential indications. 
Rivaroxaban is marketed under trade name XARELTO.
1.1.2.
Efficacy and Safety Profile Based on Clinical Studies
The efficacy and safety of rivaroxaban has been studied in several large clinical development
programs for the prevention and treatment of multiple thrombosis-mediated conditions including 
prevention of VTE in subjects undergoing major orthopedic surgery as well as acute treatment of 
DVT and or PE.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
14
Approved, Date: 16 June 2015
A pooled analysis of 4 studies comprising the RECORD program involving 12,729 subjects
undergoing hip or knee arthroplasty demonstrated that rivaroxaban given at a dose of 10 mg once
daily compared with enoxaparin given at a dose of 30 mg twice daily or 40 mg once daily
significantly reduced the risk of symptomatic VTE and mortality (odds ratio: 0.48; 95% 
confidence interval [CI]: 0.30 to 0.76), without increasing the risk of major or clinically relevant 
non-major bleeding (odds ratio: 1.17; 95% CI: 0.93 to 1.46).30
The EINSTEIN program evaluated the use of rivaroxaban alone for anticoagulant therapy for the 
treatment and prevention of acute DVT and PE. The program consisted of 3 separate but related 
studies in over 9,447 subjects assessing the safety and efficacy of rivaroxaban for the treatment 
of acute symptomatic DVT (EINSTEIN-DVT), treatment of
acute symptomatic PE 
(EINSTEIN-PE), and long-term prevention of VTE ( EINSTEIN-Extension).
The EINSTEIN-DVT study included 3,449 subjects with acute symptomatic DVT without 
symptomatic PE and demonstrated that rivaroxaban (15 mg twice daily for 3 weeks followed by 
20 mg once daily) was non-inferior to initial treatment with LMWH followed by warfarin 
(International Normalized Ratio [INR] 2.0 to 3.0).  The risk of VTE reoccurrence with 
rivaroxaban was 2.1% versus 3.0% observed with enoxaparin/VKA (hazard ratio 0.68; 95% CI: 
0.44 to 1.04).  The rate of major and non-major clinically relevant bleeding was the same in both 
groups (8.1%).
The EINSTEIN PE study is the largest single-agent study ever conducted for the treatment of 
symptomatic PE.8 In this multicenter, randomized, open-label, non-inferiority study, 4,832 
subjects with confirmed acute symptomatic PE with or without symptomatic DVT were 
recruited. Subjects were treated for a period of 3, 6, or 12 months (based on a clinical evaluation 
of individual risk for recurrent thrombosis and bleeding) with either rivaroxaban 15 mg twice 
daily for the first 3 weeks followed by 20 mg once daily thereafter, or the standard approach of 
enoxaparin 1 mg/kg twice daily transitioning to a VKA (INR of 2.0 to 3.0) started no later than 
48 hours after randomization.  Rivaroxaban was non-inferior to enoxaparin/VKA for the primary 
efficacy endpoint of recurrent symptomatic VTE (fatal plus non-fatal PE and/or DVT; 2.1% 
versus 1.8%, P=0.003 for non-inferiority). The principal safety outcome of major plus non-major 
clinically relevant bleeding occurred with a similar incidence in both study arms, but major 
bleeding occurred significantly less frequently among subjects treated with rivaroxaban as 
compared to the enoxaparin/VKA group (1.1% versus 2.2% respectively, P = 0.003).
The EINSTEIN extension study (n=1,196 subjects) evaluated if extended duration of rivaroxaban 
administration (20 mg taken once daily or 6 to 12 months) in subjects who had previously 
completed 6 to 12 months of anticoagulation therapy including rivaroxaban and VKA was 
superior to placebo with respect to the rate of recurrent VTE. VTE recurred in 1.3% of the 
rivaroxaban-treated subjects versus 7.1% of the placebo-treated subjects (p≤0.001 for 
superiority). There was no significant difference for the principal safety endpoint of major 
bleeding (0.7% in the rivaroxaban versus 0% in placebo subjects, p=0.112).
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
15
Approved, Date: 16 June 2015
The safety profile of rivaroxaban has been well established. As expected for a compound in the 
anticoagulant class of drugs, a bleeding risk is associated with the use of rivaroxaban. For the 
most comprehensive description of the safety profile of rivaroxaban, refer to the latest version of 
the Investigator's Brochure for rivaroxaban.14
1.2.
Overall Rationale for the Study
In recent years, the ability to rapidly and to accurately stratify patients with PE according to their 
risk of clinical deterioration has gained importance.2,3,14,33 Multiple clinical prognostic models 
have been developed and tested to identify low risk PE patients who may be candidates for 
outpatient care or for early discharge after an abbreviated in hospital stay. Collectively, these 
studies indicate that low risk PE patients may be prospectively identified. The most well 
validated prospective risk stratification is the Hestia criteria and Pulmonary Embolism Severity 
Index (PESI) scoring system (Table 1 and Table 2).These tools identify a cohort with a very low 
risk for bleeding and recurrent thrombosis and may be able to identify a population of PE 
patients who can be safely treated on an outpatient basis.,1 22
Table 1
Hestia Exclusion Criteria for Outpatient Treatment
Is the patient hemodynamically unstable?a
Yes
No
Is thrombolysis or embolectomy necessary?
Yes
No
Active bleeding or high risk of bleeding?b
Yes
No
More than 24 h of oxygen supply to maintain oxygen saturation >90%?
Yes
No
Is pulmonary embolism diagnosed during anticoagulant treatment?
Yes
No
Severe pain needing intravenous pain medication for more than 24 h 
(infection, malignancy, no support system)?
Yes
No
Does the patient have a creatinine clearance of <30 ml/min?c
Yes
No
Does the patient have severe liver impairment?d
Yes
No
Is the patient pregnant?
Yes
No
Does the patient have a documented history of heparin-induced 
thrombocytopenia?
Yes
No
If the answer to one of the questions is 'yes', the patient cannot be treated at home 
a
Include the following criteria, but leave these to the discretion of the investigator: systolic blood pressure <100 mmHg with 
heart rate > 100 beats/min; condition requiring admission to an intensive care unit.
b
Gastrointestinal bleeding in the preceding 14 days, recent stroke (<4 weeks ago), recent operation (< 2 weeks ago), bleeding 
disorder or thrombocytopenia (platelet count <75 x 109 L-1), uncontrolled hypertension (systolic blood pressure > 180 mmHg 
or diastolic blood pressure > 110 mmHg
c
Calculated creatinine clearance according to the Cockroft-Gault formula
d
Left to the discretion of the investigator
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
16
Approved, Date: 16 June 2015
Table 2
Original and Simplified Pulmonary Embolism Severity Index (PESI)
Variable
Original PESIa
Score
Simplified PESIb Score
Age >80 years
Age in years
1
Male sex
+10
-
History of cancer
+30
1
History of heart failure
+10
1c
History of chronic lung disease
+10
Pulse ≥ 110 beats/minute
+20
1
Systolic blood pressure < 100 mm Hg
+30
1
Respiratory rate ≥ 30 breaths/minute
+20
-
Temperature < 36°C
+20
-
Altered mental statusd
+60
-
Arterial oxygen saturation <90%e
+20
1
a
A total point score for a given patient is obtained by summing the patient's age in years and the points for each applicable 
prognostic variable. The five following risk classes are defined based on patients' total point score: class 1 (≤65 points), class 
II (65-85 points), class III (86-105 points), class IV (106-125 points), and class V (>125 points). Patients in risk classes I/II 
are considered low risk.
b
A total point score for a given patient is obtained by summing the points for each applicable prognostic variable. Patients 
with 0 points are considered low risk. 
c
The variables were combined into a single category of chronic cardiopulmonary disease. 
d
Altered mental status was defined as disorientation, lethargy, stupor, or coma. 
e
Arterial oxygen saturation was defined with and without the administration of supplemental oxygen.
While the exact number of PE patients who are very low risk candidates for early discharge is 
unknown, a recent review of the National Hospital Ambulatory Medical Care Survey 
(NHAMCS; a nationally representative weighted sampling of U.S. ED visits) evaluated adult 
patients with a primary diagnosis of PE.23 It is suggested that a large early discharge of the PE 
candidate population may exist. In this analysis of 625 million US hospital visits from 2006 to 
2010, an estimated 394,000 admissions were for PE. Due to the medications required during this 
time (heparin bridging to warfarin therapy), few PE cases were discharged from the ED and 
overall admission rates were extremely high (90%). However, only 16% of patients required 
treatment in an intensive care unit, a fact which demonstrated no significant changes over time. 
This suggests that the overwhelming majority of PE cases were cared for on a regular hospital
floor in a monitored environment, a location which, except for the addition of monitoring and 
providing IV therapy (as required for heparin bridging), provides little additional care for the low 
risk PE patient.
The recent availability of rapid onset oral anticoagulants now creates a scenario where multiple 
days of hospitalization for anticoagulation to take effect are unnecessary. To determine the 
relative size of the cohort of candidate patients that potentially can be managed in an outpatient 
environment, Singer A, et al, applied the PESI score to the NHAMCS database.24 The results 
demonstrated that overall 161,540 (41%) patients had a very low (13%, n=51,220) or low 
(28%, n=110,320) score. As low and very low PESI score correlates with mortality rates below
1%, this suggests that if an appropriate, safe, and effective therapy was available, nearly half of 
PE patients could receive initial treatment in the ED with a rapid onset oral anticoagulant and 
then be discharged directly from the ED, thus avoiding the risks and expense of in-hospital 
therapy.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
17
Approved, Date: 16 June 2015
Rivaroxaban, a rapid onset oral FXa inhibitor, has been shown to be a safe and effective 
treatment for PE. In the randomized, blinded, standard therapy controlled, 4,832 patient 
EINSTEIN PE study, patients were randomized to either standard therapy (bridging and 
warfarin) or rivaroxaban. Overall, 3,136 (64.9%) received therapy within 24 hours of 
hospitalization, with the rivaroxaban group having similar outcomes as the standard therapy 
cohort, despite the absence of a bridging period. These data strongly support the consideration 
that early treatment and discharge from the ED could safely avoid the unnecessary 
hospitalization of low-risk patients with PE.
Further, unlike warfarin, which is associated with coagulation parameter monitoring and dose 
adjustment difficulties; rivaroxaban does not require routine monitoring of coagulation 
parameters making it a more convenient option than warfarin.23 These properties of rivaroxaban 
may enhance the option of outpatient treatment for PE patients.5,8,19,33
The proposed MERCURY PE study is designed to evaluate the number of days of hospitalization
(from enrollment up to 30 days) as well as overall safety of low risk PE patients discharged from 
the ED to the home environment and treated with rivaroxaban as outpatients as compared to 
those treated with standard-of-care. Patients with PE who are at low risk for adverse outcomes, 
as defined by a Hestia score of zero, and who are candidates for treatment with anticoagulants
including LMWH or any other approved new oral anticoagulant on an outpatient basis will be 
randomized to open label early ED discharge on rivaroxaban or standard therapy.
2.
OBJECTIVES AND HYPOTHESIS
2.1.
Objectives
Primary Objective
The primary objective of the study is to demonstrate that low risk PE patients who are discharged 
from the ED to the home environment and treated with rivaroxaban as outpatients have fewer 
total days in the hospital for bleeding and/or VTE events through Day 30 compared to patients 
who are treated with initial hospitalization and standard-of-care.
Secondary Objective
The secondary objective of the study is to assess the reoccurrence of symptomatic, objectively 
confirmed VTE, defined as recurrent PE or new or recurrent DVT (including symptomatic upper 
extremity DVT) or VTE related death within 90 days of randomization.
Exploratory Objective
The exploratory objective of this study is to evaluate patient outcomes by baseline risk factors.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
18
Approved, Date: 16 June 2015
2.2.
Hypothesis
Clinical:
The clinical hypothesis is that an early discharge strategy for low risk PE patients, identified in 
the ED, and discharged to the home environment and treated with rivaroxaban as outpatients will 
result in fewer days in the hospital for bleeding and/or VTE events through Day 30 than patients 
treated with standard-of-care.
Safety:
The safety hypothesis is that major bleeding rates as assessed by the International Society on 
Thrombosis and Haemostasis (ISTH) criteria at 90 days of randomized treatment will be similar 
between the rivaroxaban and standard-of-care strategies.
3.
STUDY DESIGN AND RATIONALE
3.1.
Overview of Study Design
This is a randomized, open-label, parallel-group, multicenter study conducted in the US. Eligible 
subjects will include men and women, 18 years of age and older, who have a confirmed 
diagnosis of acute, symptomatic PE with or without symptomatic DVT. Approximately 300 PE 
subjects presenting to the ED and assessed as being at low risk of clinical deterioration using the 
Hestia criteria will be randomized in a 1:1 ratio to one of two treatment strategies: 1) rivaroxaban 
and discharge from the ED to the home environment or 2) standard-of-care (as per local protocol 
and defined by the medical team caring for the subject). All subjects will be followed for 90 days 
after starting randomized treatment. Subjects meeting all inclusion and no exclusion criteria will 
be eligible for enrollment.
The Hestia criteria are predefined, validated clinical criteria that can be used to identify patients 
with PE who are at low risk for subsequent clinical deterioration and who are candidates for 
anticoagulant treatment on an outpatient basis.  
The study consists of a Screening and Randomization Period, followed by a 90-day open-label 
treatment period, and an end of study/early withdrawal (EOS) visit. The duration of study 
participation for each subject is approximately 3 months.
Subjects will undergo screening in the ED and must be randomized within 12 hours after 
confirmation of PE diagnosis. All bleeding events (ISTH major and clinically relevant 
non- major bleeding events) and efficacy events (VTE related death, recurrence of PE or new or 
recurrent DVT) and all deaths during the study will be adjudicated in a blinded manner by a 
Clinical Endpoints Committee (CEC). Events will be adjudicated throughout the entire 90 days 
of randomized treatment. The CEC will independently review clinical events data as they 
become available, and will adjudicate and will classify deaths, bleeding events, and recurrence of 
PE and new or recurrent DVT in a consistent and unbiased manner.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
19
Approved, Date: 16 June 2015
An Independent Data Monitoring Committee (DMC), an Executive Committee (EC) and Study 
Coordinator Operational Committee (SC OC) will be commissioned for this study. The DMC 
will monitor the progress of the study and will periodically review safety data. The DMC will 
follow guidelines specified in the DMC charter to ensure timely completion of planned and 
routine safety data reviews and analyses of the accumulating study data at prespecified time(s) 
and prepare its recommendations accordingly. The EC will review recommendations from the 
DMC regarding safety analyses and/or study modifications and will oversee implementation, if 
necessary, of these study modifications. The SC OC will provide input to the operational 
logistics regarding study design and conduct of the study. Additional information is provided in 
Section 11.5, Committees.
The frequency and timing of efficacy, safety, and other measurements are provided in the Time 
and Events Schedule.
A diagram of the study design is provided below in Figure 1.
Figure 1:
Study Diagram: Clinical Protocol 39039039APE4001
3.2.
Study Design Rationale
Study Population
The study population includes subjects with acute symptomatic PE with or without symptomatic 
DVT who are deemed to be at low risk of subsequent clinical deterioration. 
The exclusion criteria selected are derived from the Hestia study, a prospective cohort study
conducted in 12 hospitals in The Netherlands between 2008 and 2010. The objective of the 
Hestia study was to confirm the results of several small observational cohort studies in a large 
study, and to demonstrate that the incidences of VTE recurrence, major bleeding, and mortality 
are very low in patients selected for outpatient treatment with a simple set of exclusion criteria. 
The Hestia study population included patients with objectively proven acute PE who were 
triaged with the predefined criteria for eligibility for outpatient treatment, with LMWH 
(nadroparin) followed by VKA. Patients were deemed eligible for outpatient treatment if they 
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
20
Approved, Date: 16 June 2015
answered no to each of the exclusion criteria listed under exclusion criteria #1 (see Section 4.2) 
of this protocol. All patients eligible for outpatient treatment were sent home either immediately 
or within 24 hours after a PE was objectively diagnosed. Outpatient treatment was evaluated 
with respect to recurrent VTE, including PE or DVT, major hemorrhage and mortality during
3 months of follow-up. Patients meeting the following inclusion criteria, were potentially 
eligible: over 18 years of age with objectively proven acute PE presenting to the ED or outpatient 
clinic. Patients with asymptomatic or chronic PE, defined as duration of symptoms lasting for 
longer than 14 days and no acute worsening within the last 14 days, were not eligible for 
enrollment. The Hestia study population experienced a 2% rate of VTE reoccurrence, a 1% rate 
of all-cause mortality, and a 0.7% rate of major bleeding by day 90. These data suggest that the 
low-risk PE patients prospectively identified using the Hestia inclusion criteria can be safely 
treated on an outpatient basis as demonstrated by low rates of VTE recurrence, mortality, and 
bleeding.33
Rivaroxaban Dosage
The selected dose in this study is approved for the treatment of DVT and/or PE and for the 
reduction in the risk of recurrence of DVT and of PE. Rivaroxaban will be administered per the 
United States Package Insert at an initial dose of 15 mg taken orally twice daily with food for the 
first 21 days followed by a dose of 20 mg taken orally once daily with food, at approximately the 
same time each day for approximately 69 days for a total duration of 90 days.
Missed Dose
If a dose of rivaroxaban is not taken at the scheduled time, administer the dose as soon as 
possible on the same day as follows:

For subjects receiving 15 mg twice daily: The subject should take rivaroxaban immediately 
to ensure intake of 30 mg rivaroxaban per day. In this instance, two 15 mg tablets may be 
taken at once. The subject should continue with the 15 mg twice daily regimen on the 
following day.

For subjects receiving 20 mg once daily: The subject should take the missed rivaroxaban 
dose immediately.
Patient-Reported Outcome 
The Anti-Clot Treatment Scale (ACTS) is a validated measure of patient treatment satisfaction
that focuses on all aspects of anticoagulant treatment, both positive and negative. As part of the 
EINSTEIN DVT study, patients reported greater satisfaction in the rivaroxaban group compared 
with the enoxaparin/VKA group as demonstrated by ACTS Burdens and ACTS Benefits.5 The 
improved scores seen with rivaroxaban treatment consistently across both tests provide further 
and more general support to the anticoagulation-specific effects seen with the ACTS scores 
alone. 
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
21
Approved, Date: 16 June 2015
As part of the EINSTEIN PE study, 2,397 patients in 7 countries were asked to complete the 
ACTS throughout the duration of treatment of up to 12 months.23  Therefore, in both the 
EINSTEIN PE and EINSTEIN DVT patient satisfaction substudies, increases in ACTS Burdens 
scores with rivaroxaban were more pronounced over time compared with ACTS Benefits scores.
The lower treatment burden may reflect the convenience offered by rivaroxaban compared with 
standard dual-drug therapy, including few drug interactions, a lack of dietary restrictions and no 
requirement for regular coagulation monitoring. Given that reduced treatment burden and 
regimen complexity are associated with better compliance, the reduced burden and monotherapy 
approach associated with rivaroxaban may contribute to increasing patient adherence to 
anticoagulant treatment, thereby improving clinical efficacy and outcomes in VTE patients.23
The Site-of-Care questionnaire is based on literature findings evaluating the location of care, ie, 
home versus hospital. This questionnaire assesses the patients’ satisfaction and preference to 
location of care received, as well as their overall satisfaction with the care provided.
Open-Label, Randomized Design 
An open-label study design is appropriate as blinding is not practical under the proposed study 
design, nor is it necessary when the main goal of the study is to evaluate treatment strategies in 
low-risk PE patients. The clinical and safety events in this study will be evaluated and 
appropriately adjudicated by a blinded CEC panel.
Randomization will be used to minimize bias in the assignment of subjects to treatment strategies
and to increase the likelihood that known and unknown subject attributes (eg, demographic and 
baseline characteristics) are evenly balanced across treatment strategies.
Rationale for Duration of Therapy
The projected duration of 90 days of subject exposure to study drug was selected for low risk PE 
patients per the CHEST guideline panel. In a prospective observational study of 1,180 inpatients 
categorized by a predefined risk assessment model, hospitalized patients were categorized as 
either low or high risk for VTE. Attending physicians were not notified of their patients' risk 
categories and patients were followed for symptomatic VTE for 90 days.16 Thus, the duration of 
the treatment period for this study was selected to be long enough to evaluate the extent to which 
rivaroxaban can safely prevent VTE events in this selected study population. This approach will 
ensure an adequate number of events in order to perform a robust primary analysis and draw 
definitive conclusions relating to the primary hypothesis.
Safety Assessments
Rivaroxaban has been evaluated in studies that include over 84,000 subjects in Phase 1 through 
multiple large Phase 4 clinical trials of the rivaroxaban clinical development program.  The 
adverse event profile of rivaroxaban has been well described and experience relative to the safe 
conduct of clinical trials is extensive. For example, over 12,000 subjects participated in the 
published Phase 3 RECORD studies of primary VTE prevention in subjects undergoing elective 
total hip/knee replacement alone. Additional characterization of the adverse event profile of 
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
22
Approved, Date: 16 June 2015
rivaroxaban will be possible using data from the EINSTEIN-DVT, EINSTEIN-PE, and
EINSTEIN-Extension trials.
Given the extensive background of existing safety data, only serious adverse events (SAE), 
adverse events leading to discontinuation of study drug, and adverse events of particular concern 
to the investigator (see Sections 9.5, Safety Evaluations and 12.1, Adverse Events Definitions)
will be collected in this study.
Biomarker Collection
A blood sample for biomarkers will be collected at screening from all subjects who give their 
consent for this blood sample. Biomarker samples will be used for research related to 
rivaroxaban, analysis of molecules involved in the clotting pathway, study comedications, and/or 
PE. They may also be used to develop tests/assays related to rivaroxaban, study comedications or 
PE.
Medical Resource Utilization and Health Economics
Treatment of the anticoagulant disease state in patients with acute PE with rivaroxaban versus 
inpatient hospitalization and local standard-of-care may result in lower length of stay (LOS) and 
unscheduled visits; therefore comparisons will be done across treatment strategies. Length of 
initial and subsequent hospitalizations as well as all-cause and VTE related re-hospitalizations 
due to recurrence will be economically evaluated.
4.
SUBJECT POPULATION
Screening for eligible subjects will be performed in the ED. Subjects will be assessed to be at 
low risk for clinical deterioration in the ED and should be randomized within 12 hours after 
confirmation of PE diagnosis.
The inclusion and exclusion criteria for enrolling subjects in this study are described in the 
following 2 subsections. If there is a question about the inclusion or exclusion criteria below, the 
investigator should consult with the appropriate sponsor representative before enrolling a subject 
in the study.
For a discussion of the statistical considerations of subject selection, refer to Section 11.2, 
Sample Size Determination.
4.1.
Inclusion Criteria
Each potential subject must satisfy all of the following criteria to be enrolled in the study. Each 
subject must:
1.
Be a man or woman ≥18 years of age.
2.
Have confirmed acute symptomatic PE with or without symptomatic DVT.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
23
Approved, Date: 16 June 2015
3.
Be a PE patient diagnosed in the ED who is deemed to be at low risk of clinical 
deterioration as determined by the Hestia criteria.
Note: Pulmonary embolism diagnosis is defined as the acute onset of dyspnea, chest 
pain, dizziness, tachycardia, and/or palpitations confirmed per local standard-of-care 
with imaging techniques such as Computed Tomography
(CT),
Pulmonary 
Angiography, or Pulmonary Ventilation/Perfusion scan.
4.
Have no contraindications to and be able to complete randomized treatment and all 
study assessments.
5.
Be able to be randomized within 12 hours after confirmation of PE diagnosis and be 
assessed as able to be discharged from the ED after the initiation of randomized therapy.
6.
Before randomization, a woman must be either:

Not of childbearing potential: premenarchal; postmenopausal (>45 years of age 
with amenorrhea for at least 12 months; permanently sterilized (eg, bilateral tubal 
occlusion [which includes tubal ligation procedures as consistent with local 
regulations], hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or 
otherwise be incapable of pregnancy,

Of childbearing potential and practicing a highly effective method of birth control 
consistent with local regulations regarding the use of birth control methods for 
subjects participating in clinical studies: eg, established use of oral, injected or 
implanted hormonal methods of contraception; placement of an intrauterine device  
or 
intrauterine 
system; 
barrier 
methods: 
condom 
with 
spermicidal 
foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault 
caps) with spermicidal foam/gel/film/cream/suppository; male partner sterilization 
(the vasectomized partner should be the sole partner for that subject); true 
abstinence (when this is in line with the preferred and usual lifestyle of the subject).
Note: If the childbearing potential changes after start of the study (eg, woman who 
is not heterosexually active becomes active, premenarchal woman experiences 
menarche) a woman must begin a highly effective method of birth control, as 
described above.  
7.
A woman of childbearing potential must have a negative urine pregnancy test at
screening. Serum pregnancy testing may be performed if required by local regulation.
8.
Subject must be willing and able to adhere to the prohibitions and restrictions specified 
in this protocol.
9.
Subject must have a life expectancy of at least 6 months.
10.
Each subject must sign an informed consent form (ICF) indicating that he or she 
understands the purpose of and procedures required for the study and are willing to 
participate in the study.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
24
Approved, Date: 16 June 2015
4.2.
Exclusion Criteria
Any potential subject who meets any of the following criteria will be excluded from participating 
in the study. The subject will be excluded if he or she:
1.
Answers YES to any of the Hestia criteria questions below:

Include the following criteria but left to the discretion of the investigator: 
Hemodynamically unstable as determined by the following: systolic blood 
pressure <100 mm Hg with heart rate >100 bpm; condition requiring admission 
to an intensive care unit.

Thrombolysis or embolectomy necessary.

Active bleeding or high risk for bleeding as determined by the following: 
gastrointestinal bleeding in the preceding 14 days, recent stroke (less than 4
weeks ago)  recent operation (less than 2 weeks ago), bleeding disorder or 
thrombocytopenia (platelet <75,000 at screening), uncontrolled hypertension 
(systolic >180 mm Hg or diastolic >110 mm Hg at screening).

Oxygen supply to maintain oxygen saturation > 90% >24 hours.

Pulmonary embolism diagnosed during anticoagulant treatment.

Intravenous pain medication >24 hours.

Medical or social reason for treatment in the hospital >24 hrs

Creatinine clearance of less than 30 mL/min(calculated using the Cockroft Gault 
formula using actual body weight) at screening. (See Attachment 5)

Severe liver impairment; left to the discretion of the investigator

Pregnant

Documented history of heparin-induced thrombocytopenia
2.
Combined P-gp and strong CYP3A4 inhibitors (such as but not limited to ketoconazole, 
telithromycin or protease inhibitors) use within 4 days before randomization, or planned 
use during the study. Itraconazole use within 7 days before randomization or planned 
use during the study.
3.
Combined P-gp and strong CYP3A4 inducers (such as but not limited to 
rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or 
St. John's Wort) use within 2 weeks before randomization or planned use during the 
study.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
25
Approved, Date: 16 June 2015
4.
Has contraindications to the use of any anticoagulant therapy (eg, bleeding diathesis, 
history of gastrointestinal bleeding within 1 year or coagulopathy documented at 
screening).
5.
Has known allergies, hypersensitivity, or intolerance to rivaroxaban or its excipients 
(refer to Investigator's Brochure).14
6.
Has a history of malignancy within 1 year before screening (exceptions are squamous 
and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy 
that in the opinion of the investigator, with concurrence with the sponsor's medical 
monitor, is considered cured with minimal risk of recurrence). Actively receiving 
treatment for cancer or patients undergoing treatment for cancer or palliative care or CT 
evidence suggesting undiagnosed malignancy.
7.
Has elevated troponin levels at screening ≥99th percentile for normal control patients.
8.
Has received an investigational drug (including investigational vaccines) or used an 
invasive investigational medical device within 30 days before the planned first dose of 
study drug.
9.
Has taken any disallowed therapies as noted in Section 8, Pre-study and Concomitant 
Therapy before the planned first dose of study drug.
10.
Is a woman who is pregnant, or breast-feeding, or planning to become pregnant.
11.
Has any barriers to treatment adherence or follow up (ie. alcohol abuse, illicit drug use, 
psychosis, dementia). Patients with insufficient social support for outpatient treatment, 
which will include patients unlikely to have successful follow up (homeless and
prisoners) are not eligible for participation.
12.
Has any condition for which, in the opinion of the investigator, participation would not 
be in the best interest of the subject (eg, compromise the well-being) or that could 
prevent, limit, or confound the protocol-specified assessments.
13.
Had major surgery, (eg, requiring general anesthesia) within 14 days before screening, 
or will not have fully recovered from surgery, or has surgery planned during the time the 
subject is expected to participate in the study.
Note: subjects with planned surgical procedures to be conducted under local anesthesia 
may participate.
14.
Is an employee of the investigator or study site, with direct involvement in the proposed 
study or other studies under the direction of that investigator or study site, as well as 
family members of the employees or the investigator.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
26
Approved, Date: 16 June 2015
15.
Has a history of human immunodeficiency virus (HIV) antibody positive, or tests 
positive for HIV at screening.
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If a subject's status changes (including laboratory results or receipt of additional medical records) 
after screening but before the first dose of study drug is given such that he or she no longer meets
all eligibility criteria, then the subject should be excluded from participation in the study. 
Section 17.4, Source Documentation, describes the required documentation to support meeting 
the enrollment criteria.
4.3.
Prohibitions and Restrictions 
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study to be eligible for participation:
1.
Non-steroid anti-inflammatory drugs and antiplatelet agents are discouraged, however, 
non-steroidal anti-inflammatory drugs – for occasional use only (defined as less than 2 
weeks of daily dosing) are allowed.
2.
Dual aspirin and clopidogrel therapy is prohibited.
3.
A woman of childbearing potential who is heterosexually active must remain on a 
highly effective method of birth control (see inclusion criteria).
Refer to Section 8 Prestudy and Concomitant Therapy for details regarding prohibited and 
restricted therapy during the study.
5.
TREATMENT ALLOCATION AND BLINDING
Treatment Allocation
Procedures for Randomization and Stratification
The principle purpose of randomization is to ensure unbiased treatment assignment in a manner 
that assures minimum allocation bias, and balancing both known and unknown prognostic 
factors at the baseline. Subjects will be randomly assigned in a 1:1 ratio to the outpatient group 
to receive rivaroxaban or to the inpatient group to receive standard-of-care. The treatment 
assignment is based on a computer-generated randomization schedule prepared before the study 
by or under the supervision of the sponsor. The randomization will be balanced by using 
randomly permuted blocks and will be stratified by study centers.
Blinding
As this is an open label study, blinding procedures are not applicable.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
27
Approved, Date: 16 June 2015
6.
DOSAGE AND ADMINISTRATION
Subjects will be randomly assigned to 1 of 2 treatment strategies in a 1:1 ratio:

Rivaroxaban at an initial dose of 15 mg taken orally twice daily with food for the first 
21 days followed by a dose of 20 mg taken orally once daily with food, at approximately the 
same time each day for approximately 69 days for a total treatment duration of 90 days.  

The first rivaroxaban dose should be administered in the ED as soon as possible after 
randomization. 

If the patient has received prerandomization anticoagulant therapy:  
o
Rivaroxaban should be planned 4 hours after the bolus injection or stopping the 
infusion with unfractionated heparin (UFH) or within 6 to 12 hours after the last 
injection of LMWH with a twice-daily regimen, or within 12 to 24 hours after the 
last injection of LMWH with a once-daily regimen, or 12 to 24 hours after last 
injection of fondaparinux.
OR

Standard-of-care (per local protocol and defined by the medical team caring for the subject)
Missed Dose
If a dose of rivaroxaban is not taken at the scheduled time, administer the dose as soon as 
possible on the same day as follows:

For subjects receiving 15 mg twice daily: The subject should take rivaroxaban immediately 
to ensure intake of 30 mg rivaroxaban per day. In this instance, two 15 mg tablets may be 
taken at once. The subject should continue with the regular 15 mg twice daily regimen as 
recommended on the following day.

For subjects receiving 20 mg once daily: The subject should take the missed rivaroxaban 
dose immediately.
Transition from Study Drug to Other Therapy at the End of Study
The decision of how best to manage the patient after the end of this study will be made by the 
clinical investigator and the patient’s physician (See Attachment 2).
Study-site personnel will instruct subjects on how to store study drug for at-home use as 
indicated for this protocol. Rivaroxaban should be stored at room temperature. (See Section 14.4,
Preparation, Handling, and Storage).
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
28
Approved, Date: 16 June 2015
6.1.
Temporary Discontinuation of Study Drug
If the investigator determines that anticoagulation must be temporarily discontinued to reduce the 
risk of bleeding with surgical or other procedures:
Rivaroxaban should be stopped at least 24 hours before the procedure to reduce the risk of 
bleeding. In deciding whether a procedure should be delayed until 24 hours after the last dose of 
rivaroxaban, the increased risk of bleeding should be weighed against the urgency of 
intervention. Rivaroxaban should be restarted after the surgical or other procedures as soon as 
adequate hemostasis has been established, noting that the time to onset of therapeutic effect is 
short. If oral medication cannot be taken during or after surgical intervention, consider 
administering a parenteral anticoagulant.
Study drug should be temporarily discontinued if the subject:

Experiences a major bleeding event. For less severe bleeding events, investigator 
discretion is allowed. If possible, study drug should be resumed when the bleeding event 
has resolved and the cause has been identified and corrected.

Has a SAE that is considered by the investigator to be possibly related to, or exacerbated 
by, study drug administration.

Requires a prohibited therapy on a temporary basis (see Section 8, Prestudy and 
Concomitant Therapy).
Study drug can be resumed when the investigator considers it safe to do so. If more than 5
consecutive days of study drug is missed, the subject will permanently discontinue study drug 
and have end-of-treatment visit assessments performed (see Section 9.1.3, Open-Label 
Treatment Phase).
7.
TREATMENT COMPLIANCE
Study drug will be self-administered by subjects; the number of study drug tablets dispensed will 
be recorded and compared with the number returned. Subjects will receive instructions on 
compliance with study drug administration at the randomization visit. During the course of the 
study, the investigator or designated study-site personnel will be responsible for providing 
additional instruction to reeducate any subject who is not compliant with taking the study drug.  
In addition, during the follow-up phone calls at Days 3, 7, and 14, the Study Coordinator will 
confirm that the standard-of-care patients have obtained their medications and that all patients, 
including those in the rivaroxaban group, are taking them as directed and have no questions.
Study personnel will maintain a log of all study drug dispensed. Drug supplies for each subject
randomized to rivaroxaban will be inventoried and reconciled throughout the study. Subjects in 
the standard-of-care treatment strategy will be asked about treatment compliance throughout the 
study. Subjects should report any missed doses. The study personnel should discuss reasons for 
missed doses with subjects to ascertain if the missed dose was related to study endpoints or 
safety. It is understood that subjects may occasionally miss a dose or that a subject may be 
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
29
Approved, Date: 16 June 2015
placed on temporary discontinuation (see Section 6.1, Temporary Discontinuation of Study 
Drug). Any unexplained missed doses that result in the subject returning more than 20% of the 
prescribed study drug will be considered noncompliance. The investigator should contact the 
medical monitor to discuss any unexplained study drug non-compliance.
8.
PRESTUDY AND CONCOMITANT THERAPY
Allowed Therapy

A previous dose of VKA and/or LMWH/UFH is allowed prior to randomization.

Antiplatelet agents are discouraged. However if indicated, aspirin up to a dose of 
100 mg/day is allowed. Clopidogrel up to a dose of 75 mg/day or alternative P2Y12 
inhibitors are allowed (Prasugrel 10 mg/day or ticagrelor 90 mg twice daily).
Medicines that reduce gastric acid (eg, H2 antagonists or proton-pump inhibitors) may 
reduce the incidence of gastrointestinal bleeding in subjects who are treated with 
anticoagulants, and unless contraindicated, their use should be considered.
Prohibited Therapy

Combined P-gp and strong CYP3A4 inhibitors (such as but not limited to ketoconazole, 
telithromycin or protease inhibitors) use is prohibited within 4 days before randomization, or 
during the study. Itraconazole use is prohibited within 7 days before randomization and 
during the study.

Combined P-gp and strong CYP3A4 inducers (such as but not limited to 
rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or St. 
John's Wort) use is prohibited within 2 weeks before randomization or during the study.

Dual anti-platelet therapy is prohibited.
All prestudy therapies (prescription or over-the-counter medications, including vaccines, 
vitamins, herbal supplements); administered up to 14 days before first dose of study drug must 
be recorded at screening.
All concomitant therapies administered at the time of an occurrence of an adverse event must be 
recorded in the electronic case report form (eCRF). Concomitant therapies should be recorded 
beyond EOS visit only in conjunction with SAEs that meet the criteria outlined in Section 12.3.2,
Serious Adverse Events.
All therapies (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; different from the study drug must be recorded in the eCRF. Recorded information 
will include a description of the type of the drug, treatment period, dosing regimen, route of 
administration, and its indication. Modification of an effective preexisting therapy should not be 
made for the explicit purpose of entering a subject into the study.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
30
Approved, Date: 16 June 2015
9.
STUDY EVALUATIONS
9.1.
Study Procedures
9.1.1.
Overview
The Time and Events Schedule summarizes the frequency and timing of efficacy and safety 
measurements applicable to this study.
All visit-specific patient-reported outcome (PRO) assessments should be conducted before any 
tests, procedures, or other consultations for that visit to prevent influencing subject perceptions.
Additional serum or urine pregnancy tests may be performed, as determined necessary by the 
investigator or required by local regulation, to establish the absence of pregnancy at any time 
during the subject's participation in the study.
The total blood volume for each subject in the study is approximately 6 mL for safety. Subjects 
who give consent to the collection of an optional biomarker sample will have an additional 
10 mL drawn for a total blood volume of 16 mL.
Volume of Blood to be Collected From Each Subject 
Type of Sample
Volume per 
Sample (mL)
No. of Samples 
per Subject
Total Volume of 
Blood (mL)a
CrCl
3.5
1
3.5
Troponin
2.5
1
2.5
Optional biomarker sample
10.0
1
10.0
Approximate Total
16.0
16.0
a
Calculated as number of samples multiplied by amount of blood per sample.
The maximum amount of blood drawn from each subject in this study will not exceed 16 mL.
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the 
samples.
9.1.2.
Screening Phase
Screening may begin at any time after consent is obtained during the time the patient is in the 
ED. Subjects will be screened using local laboratory results for the inclusion and exclusion
clinical laboratory parameters.
9.1.3.
Open-Label Treatment Phase
Day 1/Day of Randomization
Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be 
randomly assigned by an interactive web response system on Day 1 to 1 of 2 treatment strategies. 
Randomization must be performed while the subject is in the ED and within 12 hours after initial 
diagnosis of a PE.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
31
Approved, Date: 16 June 2015
Procedures Throughout Open-Label Treatment Phase
The study will include scheduled telephone calls and visits as outlined in the Time and Event 
Schedule. Visits by the subject to the site are permissible for management of therapy or for 
evaluation of adverse events. Patients randomized to the rivaroxaban treatment strategy may be 
treated 
as 
the
investigator 
feels 
is 
appropriate, 
including 
primary 
care 
physician/cardiologist/pulmonologist referrals and any follow-up visits/calls as indicated.  These 
interventions will be captured in the eCRF.  
Blood samples for exploratory biomarker testing will be collected from those subjects who give 
permission for this sample; see Section 9.3, Biomarkers, for additional information.
End of Treatment/Early Termination
Subjects will have an end-of-treatment/early withdrawal visit at Day 90, or at the time of early 
treatment discontinuation or early withdrawal. At this visit, investigators must ensure that all 
subjects are started on adequate anticoagulation, as indicated, based upon local standards. 
Additional guidance is provided in Section 6.1, Temporary Discontinuation of Study Drug and 
Attachment 2.
Reasons for withdrawal from the study are presented in Section 10.2, Withdrawal From the 
Study. If a subject permanently withdraws before the end of the open-label treatment phase, he 
or she will have end-of-treatment/early withdrawal visit assessments performed as soon as 
possible and no more than 5 days after the last dose of study drug. For these subjects, this visit 
will serve as the last data collection point for endpoints in this study, with the exception of the 
patient’s vital status at what would have been the time of study completion.
Subjects who do not complete the study will have their vital status and any bleeding or VTE 
related events collected at Day 90, either by telephone or in person, or if applicable, by a review 
of the subject's medical record or available public records, unless this contact is not allowed by 
local regulations.  
9.2.
Efficacy 
9.2.1.
Evaluations
Local standards of VTE diagnosis are acceptable in patients who are symptomatic for VTE.  
Such radiologic procedures for PE diagnosis include CT, Pulmonary Angiography, catheter 
pulmonary angiogram, and lung ventilation / perfusion lung scan.  Symptomatic DVT may be 
diagnosed by ultrasonography or venography.
All bleeding events (ISTH major and clinically relevant non-major bleeding events) and efficacy 
events (VTE related death, recurrence of PE or new or recurrent DVT) and all deaths during the 
study will be adjudicated in a blinded manner by a CEC; these events will be adjudicated 
throughout the entire 90 days of randomized treatment.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
32
Approved, Date: 16 June 2015
The following definitions will be applied by the CEC to confirm a suspected episode of 
recurrent PE/DVT:
Suspected (recurrent) PE with one of the following findings:

a (new) intraluminal filling defect in segmental or more proximal branches on CT,

a (new) intraluminal filling defect or an extension of an existing defect or a new sudden cut-
off of vessels more than 2.5 mm in diameter on the pulmonary angiogram,

a (new) perfusion defect of at least 75% of a segment with a local normal ventilation result 
(high-probability) on ventilation/perfusion lung scintigraphy.

inconclusive CT, Pulmonary Angiography, or lung ventilation/perfusion scintigraphy with 
demonstration of DVT in the lower extremities by compression ultrasound or venography.
Suspected (recurrent) DVT with one of the following findings if there were no previous DVT 
investigations:

abnormal compression ultrasound 

an intraluminal filling defect on venography.
Suspected (recurrent) DVT with one of the following findings if there was a DVT investigation 
at screening:

abnormal compression ultrasound where compression had been normal or, if non-
compressible during screening, a substantial increase (4 mm or more) in diameter of the 
thrombus during full compression,

proximal extension of an intraluminal filling defect, or a new intraluminal filling defect, or

proximal extension of non-visualization of veins in the presence of a sudden cut-off on 
venography.
All Deaths

PE based on objective diagnostic testing, autopsy, or death which cannot be attributed to a 
documented cause and for which PE/DVT cannot be ruled out (unexplained death).

In the absence of objective testing, a suspected episode of DVT or PE will be considered as 
confirmed if it led to a change in anticoagulant treatment at therapeutic dosages for more 
than 2 days.
9.2.2.
Endpoints 
Primary Endpoint
Clinical
The primary clinical endpoint is the number of days of initial inpatient hospitalization (beginning 
from randomization to discharge from the hospital) plus any subsequent hospitalization(s) related 
to bleeding and/or VTE events up to 30 days.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
33
Approved, Date: 16 June 2015
Secondary Endpoints

Reoccurrence of symptomatic, objectively confirmed VTE, defined as recurrent PE or new 
or recurrent DVT (including symptomatic upper extremity DVT) or VTE related death 
within 90 days of randomization.

Number of unplanned hospital or physician office visits for VTE symptoms and/or bleeding
through 90 days.

Length of initial and subsequent hospitalization(s) for any reason through Day 90.

Patient-reported outcomes will be captured at Day 7 for Site-of-Care Satisfaction and Days
14, 30, and 90 for ACTS.

Length of initial and subsequent hospitalization(s)
as well as, VTE
related re-
hospitalization(s) due to recurrence will be economically evaluated.
Exploratory Endpoint
Outcomes by baseline risk factors will be evaluated.
9.3.
Biomarkers 
A blood sample to evaluate troponin levels will be obtained at screening in order to determine 
study eligibility.
A blood sample will be collected for exploratory biomarker testing from all subjects who give 
permission for this sample. Subjects who consent to this optional blood sample collection will be 
asked to provide 1 blood sample which will be stored and used for validation of a biomarker 
assay.
9.4.
Patient-Reported Outcomes 
Treatment and Site-of-Care satisfaction will be assessed. At follow-up visits Day 14, Day 30,
and Day 90 treatment satisfaction will be assessed using a validated measure for treatment 
satisfaction: the ACTS.
The Satisfaction to Site-of-Care questionnaire (standard-of-care versus early discharge on 
rivaroxaban therapy) will be administered after 7 days on anticoagulant therapy.
(See Attachment 4)
The ACTS is comprised of 2 subscales: Burdens (12 items) and Benefits (3 items). The treatment 
experience scores range from ‘Not at all’ to ‘Extremely’ on a five-point Likert scale 
(psychometric rating); higher scores indicate greater satisfaction with treatment.
Satisfaction to Site-of-Care (hospitalization versus home care) rates the patient’s level of 
satisfaction to care and location with care received as well as preference to location of care 
provided.  Patients rate the 3 items of this scale of 1=Very satisfied; 2=Quite satisfied; 
3=Neither; 4=Quite dissatisfied; and 5=Very dissatisfied for satisfaction questions and for the 
one preference question responses include 1=In the hospital; 2=In the community; and 3=No 
preference.  This satisfaction scale will be administered after 1 week on anticoagulant therapy. 
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
34
Approved, Date: 16 June 2015
Statistical testing generating p values will be calculated for comparisons of hospital care and 
home care.
Medical Resource Utilization and Health Economics
Medical resource utilization and health economics data, associated with medical encounters, will 
be collected in the eCRF by the investigator and study-site personnel for all subjects throughout 
the study. Length of initial and subsequent hospitalizations as well as, all-cause and VTE related 
re-hospitalizations due to recurrence will be economically evaluated.
9.5.
Safety Evaluations
The primary safety endpoint is ISTH major bleeding at Day 90.
The secondary safety endpoints are VTE related death within 90 days of randomization and 
overall safety defined as a composite of ISTH major bleeding, clinically relevant non-major
bleeding, and mortality.
The study will include the following evaluations of safety according to the timepoints provided 
in the Time and Events Schedule: 
All bleeding events will be captured as an Adverse Event (AE) of special interest

Primary safety:  ISTH major bleeding

Secondary safety: Clinically relevant non-major bleeding
Any clinically relevant changes occurring during the study must be recorded on the Adverse 
Event section of the eCRF.
Any clinically significant abnormalities persisting at the end of the study/early withdrawal will 
be followed by the investigator until resolution or until a clinically stable endpoint is reached.
9.5.1.
Bleeding Events
The study will use the ISTH Bleeding Event Classification Scale to assess bleeding events as 
major, clinically relevant non-major bleeding, or minimal bleeding. Similar to efficacy 
outcomes, the same independent CEC will adjudicate and will classify bleeding events according 
to definitions in the CEC charter.
The principal safety outcome for this study is major bleeding using validated ISTH bleeding 
criteria. Other safety outcomes are clinically relevant non-major bleeding. 
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
35
Approved, Date: 16 June 2015
An ISTH major bleeding event is defined as overt bleeding associated with:

A fall in hemoglobin of 2 g/dL or more, or

A transfusion of 2 or more units of packed red blood cells or whole blood, or

A critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular 
with compartment syndrome, retroperitoneal, or

A fatal outcome.
Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for 
major bleeding but associated with medical intervention, unscheduled contact (visit or telephone 
call) with a physician (temporary) cessation of study treatment, or associated with discomfort for 
the subject such as pain or impairment of activities of daily life. 
Examples of clinically relevant non-major bleeding are:

Epistaxis if it lasts for more than 5 minutes, if it is repetitive (ie, 2 or more episodes of true 
bleeding, ie, not spots on a handkerchief, within 24 hours), or leads to an intervention 
(packing, electrocautery, etc.)

Gingival bleeding if it occurs spontaneously (ie, unrelated to tooth brushing or eating),or if it 
lasts for more than 5 minutes.

Hematuria if it is macroscopic, and either spontaneous or lasts for more than 24 hours after 
instrumentation (eg, catheter placement or surgery) of the urogenital tract.

Macroscopic gastrointestinal hemorrhage: at least 1 episode of melena or hematemesis, if 
clinically apparent.

Rectal blood loss, if more than a few spots.

Hemoptysis, if more than a few speckles in the sputum, or

Intramuscular hematoma

Subcutaneous hematoma if the size is larger than 25 cm2 or larger than 100 cm2 if
provoked

Multiple source bleeding
Minimal bleeding is defined as all other overt bleeding episodes that do not meet the ISTH 
criteria for major or clinically relevant non-major bleeding.
Details of all bleeding events will be captured in the eCRF. 
9.5.2.
Other Safety Assessments
Adverse Events
Adverse events will be reported by the subject (or, when appropriate, by a caregiver, surrogate, 
or the subject's legally acceptable representative) for the duration of the study. Adverse events 
will be followed by the investigator as specified in Section 12, Adverse Event Reporting.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
36
Approved, Date: 16 June 2015
Clinical Laboratory Tests 
Results of clinical laboratory tests from the local laboratory will be used at the screening visit to 
confirm eligibility of potential subjects. 
Separate laboratory tests will likely be part of the subjects’ hospital evaluation, but are not 
required by the protocol. No pre-specified laboratory tests will be performed for the duration of 
the study. However, these subjects are likely to have local laboratory tests performed during their 
hospitalization. Any laboratory test along with reference ranges relevant to a SAE or an outcome 
event should be recorded on the appropriate eCRF page.
The following tests results with reference ranges will be obtained from the hospital 
laboratory/local laboratory at the time of screening and randomization:

Troponin

Serum creatinine (CrCl to be calculated using Cockcroft-Gault formula (See Attachment 5)
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the eCRF. The 
laboratory reports must be filed with the source documents.
Additional tests may be performed by the local laboratory as usual care, but these results will not 
be captured in the eCRF unless a result constitutes an AE/SAE.
Electrocardiogram
If blood sampling or vital sign measurement is scheduled for the same time point as 
electrocardiogram (ECG) recording, the procedures should be performed in the following order: 
ECG(s), vital signs, and blood draw.
Vital Signs: temperature, pulse/heart rate, respiratory rate, and blood pressure.
Physical Examination 
The extent of the physical examination will be conducted by the site per usual local standard-of-
care.
9.6.
Sample Collection and Handling
The date and of sample collection must be recorded in the eCRF. If blood samples are collected 
via an indwelling cannula, an appropriate amount (1 mL) of serosanguineous fluid slightly 
greater than the dead space volume of the lock will be removed from the cannula and discarded 
before each blood sample is taken. After blood sample collection, the cannula will be managed 
per local practice. 
Refer to the Time and Events Schedule for the timing and frequency of all sample collections.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
37
Approved, Date: 16 June 2015
10.
SUBJECT COMPLETION/WITHDRAWAL
10.1.
Completion
A subject will be considered to have completed the study if he or she has completed assessments 
at Day 90 of the open-label phase or has experienced a clinical endpoint that precludes further 
continuation in the study. Subjects who prematurely discontinue study treatment for any reason 
before completion of the open-label phase will not be considered to have completed the study.
10.2.
Withdrawal From the Study
A subject will be withdrawn from the study for any of the following reasons:

Lost to follow-up

Withdrawal of consent

Death

Noncompliance defined as any unexplained missed doses that result in the subject's
returning more than 20% of the prescribed study drug. The investigator should contact the 
medical monitor to discuss any unexplained study drug non-compliance.

Discontinuation of study treatment. A subject's study treatment will be discontinued if:

The investigator or sponsor believes (eg, that for safety or tolerability reasons such as 
an adverse event) it is in the best interest of the subject to discontinue treatment

The subject becomes pregnant
If a subject discontinues study treatment before the end of Day 90, end-of-treatment assessments
should be obtained.
If a subject is lost to follow-up, every reasonable effort must be made by the study site personnel 
to contact the subject to determine the reason for discontinuation/withdrawal. The measures 
taken to follow up must be documented.
When a subject withdraws before completing the study, the reason for withdrawal is to be 
documented in the eCRF and in the source document. Study drug assigned to the withdrawn 
subject may not be assigned to another subject. Subjects who withdraw will not be replaced. If a 
subject withdraws from the study early, the end-of-treatment assessments should be obtained.
A vital status (alive/dead) should be completed on all randomized subjects who do not complete 
the study, regardless of the reason for discontinuation. This vital status should be completed at 
what would have been at Day 90 (±5 days). If the final study assessments are completed for an 
early discontinued subject at Day 90 time point, a vital status is not required.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
38
Approved, Date: 16 June 2015
Withdrawal From the Use of Samples in Future Research
The subject may withdraw consent for use of samples for research (refer to Section 16.2.5, 
Long-Term Retention of Samples for Additional Future Research). In such a case, samples will 
be destroyed after they are no longer needed for the clinical study. Details of the sample 
retention for research are presented in the ICF.
11.
STATISTICAL METHODS
Statistical analysis will be done by the sponsor or under the authority of the sponsor. A general 
description of the statistical methods to be used to analyze the data is outlined below. Specific 
details will be provided in the Statistical Analysis Plan. 
11.1.
Subject Information
Demographic data and baseline characteristics of all subjects will be summarized by treatment
strategy. Summaries of continuous variables will include number of subjects, mean, median, 
minimum, maximum, and standard deviation. Summaries of categorical variables will include 
frequency and percentage of subjects in each category. Medical history data will be summarized 
by body system and will include frequency and percentages of subjects with each condition. 
Frequencies and percentages for subjects completing, discontinuing and reasons for 
discontinuations will be presented and summarized for all subjects combined and by each 
treatment strategy.
Analysis Sets
For the purpose of statistical analyses, 2 analysis populations will be considered:

Intention-to-treat (ITT) analysis set: The intention to treat analysis set includes all 
subjects who are randomized into the study.

Safety analysis set: The safety population includes all randomized subjects who take at 
least 1 dose of study drug.
11.2.
Sample Size Determination
Following pragmatic considerations, the sample size in this study was determined using 
assumptions related to the expected number of days of initial inpatient hospitalization (beginning 
from randomization to discharge from the hospital) and any subsequent hospitalization(s) related 
to bleeding and/or VTE events up to 30 days. A large-sample CI approach was used to determine 
the sample size required for estimating the difference in mean LOS between the two randomized 
groups. From Aujesky et al. 2011, the standard deviation is 1 day for the outpatient group and 
3.1 days for the inpatient group from the initial hospital stay. From the available data, the 
average days of hospitalization after discharge is less than 2 days and the percentage of patients 
with VTE related hospitalization is less than 5%.4 With this information, the contribution from 
VTE related hospitalization after discharge has a very small impact on the standard deviations 
received from the initial hospital stay which were used in the sample size calculation. A total of 
150 subjects per group will provide a two-sided 95% CI with about 0.5 day of margin of error.  
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
39
Approved, Date: 16 June 2015
The margin of error is defined as the quantity from the observed difference in means to the end 
point of the CI.
The above sample size estimate will also allow an examination of the difference in the 
recurrence of VTE events in the 2 randomized groups. The incidence of recurrent VTE events is 
generally low and largely infrequent among low-risk PE patients. In the Aujesky et al.2011
study, the 90-day recurrence rates of VTE among both inpatients and outpatients were reported 
to be less than 1% (with a 95% upper confidence limit=2.7%).4  
11.3.
Analyses for Primary and Secondary Endpoints
The primary and major secondary analyses will be based on the ITT analysis set.
Analysis for Primary Endpoint
The primary clinical endpoint is the LOS of hospitalization (for the standard-of-care and 
rivaroxaban groups) beginning from randomization through discharge from the ED plus any 
bleeding or VTE events through 30 days A two-sided 95% CI will be calculated for the 
difference in LOS for 2 treatment groups.
Analysis for Major Secondary Endpoints
A two-sided 95% CI will be calculated for the difference of reoccurrence of symptomatic, 
objectively confirmed VTE, defined as recurrent PE or new or recurrent DVT (including 
symptomatic upper extremity DVT) or VTE related death within 90 days of randomization. The 
same procedure may be applied to the reoccurrence of VTE at Day 7 and Day 30 when 
appropriate. 
A two-sided 95% CI will be calculated for the difference of ISTH major bleeding and death at 
Day 90 and for the composite of ISTH major bleeding and mortality at Day 90 when appropriate. 
The following data will be summarized: ISTH major and clinically relevant non-major bleeding, 
the total number of days alive and out of the hospital, medical contacts for any reason, including 
office and ED visits, number of unplanned hospital or physician office visits for VTE symptoms 
and/or bleeding.
Patient-reported outcomes will be captured and summarized at Day 7 for Site-of-Care 
Satisfaction and Days 14, 30, and 90 for ACTS.
11.4.
Safety Analyses
Safety analyses will be based on the safety analysis set that includes all subjects who are 
randomized and take at least 1 dose of study drug.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
40
Approved, Date: 16 June 2015
Adverse Events
The verbatim terms used in the eCRF by investigators to identify adverse events will be coded 
using the Medical Dictionary for Regulatory Activities. All reported adverse events with onset 
during the treatment phase (ie, treatment-emergent adverse events [TEAEs], and adverse events 
that have worsened since baseline) will be included in the analysis. For each adverse event, the 
percentage of subjects who experience at least 1 occurrence of the given event will be 
summarized by treatment group. Summaries, listings, datasets, or subject narratives may be 
provided, as appropriate, for those subjects who die, who discontinue treatment due to an adverse 
event, or who experience a severe or a SAE.
TEAEs, using the Medical Dictionary for Regulatory Activities, will be summarized for each 
treatment group by body system, preferred term, intensity, and relationship to the study 
treatment. A TEAE is defined as any adverse event that occurred after randomization and after 
the first intake of study treatment or that started before the first intake of study treatment and 
worsened in intensity during the active treatment period. Subjects who experienced a SAE or 
who prematurely discontinued from the study due to an adverse event will be listed. For a large 
number of subjects discontinuing due to adverse events, the distributions of the time to treatment 
discontinuation due to an adverse event will be estimated by the Kaplan-Meier estimates.
Clinical Laboratory Tests
Laboratory data will be summarized by type of laboratory test. Reference ranges and markedly 
abnormal results (specified in the Statistical Analysis Plan) will be used in the summary of 
laboratory data. Descriptive statistics will be calculated for each laboratory analyte at screening. 
A listing of subjects with any laboratory results outside the reference ranges will be provided. A 
listing of subjects with any markedly abnormal laboratory results will also be provided.
The clinical laboratory results at baseline will be summarized using descriptive statistics. The 
baseline is defined as the last measurement prior to the first dose of the randomized treatment.
Electrocardiogram 
The effects on cardiovascular variables will be evaluated by means of descriptive statistics and 
frequency tabulations for baseline ECG. 
Vital Signs
Descriptive statistics of temperature, pulse/heart rate, respiratory rate, and blood pressure 
(systolic and diastolic) resting values will be summarized at each scheduled time point. The
percentage of subjects with values beyond clinically important limits will be summarized. The 
vital sign measures at screening will be summarized using descriptive statistics. The baseline is 
defined as the last measurement prior to the first dose of the randomized treatment.
Physical Examination
Abnormal findings from the physical examinations will be listed.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
41
Approved, Date: 16 June 2015
11.5.
Committees
11.5.1.
Executive Committee
An EC will oversee the conduct and reporting of the study. The members of the EC will be 
sponsor representatives identified by the study team and will include at least 2 clinical experts.
Details will be provided in a separate EC charter.
11.5.2.
Clinical Endpoint Committee
An independent blinded CEC will apply the protocol definitions and will adjudicate and classify 
the following endpoints: ISTH major bleeding, VTE related death and overall safety defined as a 
composite of ISTH major bleeding and mortality. The CEC will include leading scientific 
investigators with coagulation, diagnostic, and statistical expertise. All bleeding events 
(ISTH major and clinically relevant non-major bleeding events), efficacy events (VTE related 
death, recurrence of PE or new or recurrent DVT) and all deaths during the study will be 
adjudicated in a blinded manner by the CEC.  Events will be adjudicated throughout the entire 
90 days of randomized treatment. The CEC will independently review clinical events data as 
they become available, and will adjudicate and classify the specified events in a consistent and 
unbiased manner. Details will be provided in a separate CEC charter.
11.5.3.
Data Monitoring Committee
The DMC will monitor the progress of the study and will periodically review safety data. After 
the review, the DMC will discuss any potential safety issues with the sponsor and will 
recommend to the EC any analyses or study modifications. The details will be provided in a 
separate DMC charter.
The DMC will consist of at least 1 medical expert in the relevant therapeutic area and at least 1 
statistician. 
11.5.4.
Study Coordinator Operational Committee 
A SC OC will provide input into the operational logistics of the study design and conduct for the 
MERCURY PE study. The committee will meet on a regular basis and will be composed of a 
minimum of 3 Study Coordinators who have expertise in conducting ED studies.  The details 
will be provided in a separate SC OC charter.
12.
ADVERSE EVENT REPORTING
Rivaroxaban has been extensively studied in Phase 1 through multiple large Phase 4 clinical 
studies involving over 84,000 patients, including over 47,000 patients exposed to rivaroxaban, 
and its overall safety profile has been well characterized. Appropriate information concerning 
adverse events were systematically collected and submitted to regulatory authorities. For the 
purposes of this study certain nonserious adverse events will not be collected, while certain 
events will be collected as endpoints and therefore not collected and reported as SAEs. All data 
on safety outcomes will be reviewed regularly by the DMC. This will be explained in 
Section 12.3.1, All Adverse Events.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
42
Approved, Date: 16 June 2015
Section 12.1.1, Adverse Event Definitions and Classifications describes the usual definitions of 
adverse events and serious adverse events.
Timely, accurate, and complete reporting and analysis of safety information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
regulatory agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity with regulatory requirements worldwide to ensure appropriate reporting of safety 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
12.1.
Definitions
12.1.1.
Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessarily 
have a causal relationship with the treatment. An adverse event can therefore be any unfavorable 
and unintended sign (including an abnormal finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not 
related to that medicinal (investigational or non-investigational) product. (Definition per 
International Conference on Harmonisation [ICH])
This includes any occurrence that is new in onset or aggravated in severity or frequency from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.1, All Adverse Events, for time of last adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and European Union Guidelines on Pharmacovigilance for 
Medicinal Products for Human Use is any untoward medical occurrence that at any dose:

Results in death

Is life-threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically might have caused death if it were more severe.)

Requires inpatient hospitalization† or prolongation of existing hospitalization

Results in persistent or significant disability/incapacity

Is a congenital anomaly/birth defect

Is a suspected transmission of any infectious agent via a medicinal product

Is Medically Important*
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
43
Approved, Date: 16 June 2015
† Note: The standard-of-care group in this study will involve a hospital admission for 
anticoagulation therapy to treat the PE.  This hospital admission for patients randomized to the 
standard-of-care group should not be reported as an SAE. However, if, during the course of the 
hospital stay, a patient in the standard-of-care group develops a reportable event, or has an event
that prolongs the hospital stay beyond the expected duration that event should be reported as an 
SAE.  If a patient in the standard-of-care group is admitted to the hospital, has an uneventful 
hospital stay and is discharged, no SAE should be reported.
All inpatient hospitalizations for patients randomized to the rivaroxaban/early discharge group
and subsequent hospitalizations for patients randomized to the standard-of-care group should be 
reported as an SAE. 
*Medical and scientific judgment should be exercised in deciding whether expedited (SAE)
reporting is also appropriate in other situations, such as important medical events that may not be 
immediately life threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above. 
These should usually be considered serious.
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity is not consistent with the 
applicable product reference safety information. For rivaroxaban, the expectedness of an adverse 
event will be determined by whether or not it is listed in the Investigator's Brochure. For a non-
sponsor investigational medicinal product with a marketing authorization, the expectedness of an 
adverse event will be determined by whether or not it is listed in the package insert.
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable or very likely by the definitions listed in Section 12.1.2, Attributes Definitions.
12.1.2.
Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg, concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely.
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg, concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
44
Approved, Date: 16 June 2015
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg, confirmed by dechallenge). An alternative explanation is less likely, eg, concomitant 
drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonably explained 
by an alternative explanation, eg, concomitant drug(s), concomitant disease(s). The relationship 
in time is very suggestive (eg, it is confirmed by dechallenge and rechallenge).
12.1.3.
Severity Criteria 
An assessment of severity grade will be made using the following general categorical 
descriptors:
Mild: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with everyday activities.
Moderate: Sufficient discomfort is present to cause interference with normal activity.
Severe: Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal everyday activities.
The investigator should use clinical judgment in assessing the severity of events not directly 
experienced by the subject (eg, laboratory abnormalities).
12.2.
Special Reporting Situations
Safety events of interest on a sponsor study drug that may require expedited (SAE) reporting 
and/or safety evaluation include, but are not limited to:

Overdose of a sponsor study drug

Suspected abuse/misuse of a sponsor study drug

Inadvertent or accidental exposure to a sponsor study drug

Unexpected therapeutic or clinical benefit from use of a sponsor study drug

Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study drug, eg, name confusion)
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
45
Approved, Date: 16 June 2015
12.3.
Procedures
12.3.1.
All Adverse Events
Adverse Events and special reporting situations, as discussed in this section, whether serious or 
non-serious, will be reported from the time a signed and dated ICF is obtained until completion 
of the subject’s last study related procedure (which may include contact for follow-up of safety). 
Serious Adverse Events, including those spontaneously reported to the investigator within 30 
days after the last dose of study drug, must be reported using the Serious Adverse Event Form. 
The sponsor will evaluate any safety information that is spontaneously reported by an 
investigator beyond the time frame specified in the protocol.
Although not required, any nonserious adverse events, of particular concern to the investigator 
may be recorded in the eCRF to bring them to the attention of the sponsor. All other non-serious 
adverse events not fulfilling the above mentioned criteria will not be reported as adverse events 
in the eCRF. (See Attachment 1)
Given the extensive existing safety data associated with rivaroxaban, study endpoint events, or 
events that appear suggestive of study endpoint events, occurring from the time of randomization 
until the EOS will not reported as serious adverse events, regardless of seriousness or severity 
and final event assessment by the CEC, unless otherwise specified. These events will be captured 
on an event page in the eCRF. Any study endpoint events or events that appear suggestive of 
endpoint events occurring prior to randomization as well as other serious adverse events and 
adverse events leading to permanent discontinuation of the study drug will be collected as 
adverse events or serious adverse events in this study independent of the final CEC assessment. 
The following study endpoint events or events that appear suggestive of a study endpoint event 
have been identified for this study.

Recurrent PE or new or recurrent DVT or VTE related event

Bleeding events

Bleeding events requiring medical attention, and/or hospitalization will be entered on 
the AE page of the eCRF; any bleeding event leading to permanent study drug 
discontinuation will also be entered on the AE page of the eCRF.
The following adverse events or SAEs will be collected and entered into the eCRF. SAEs need to 
be reported to the sponsor within the appropriate timeline as described in Section 12.3.2, Serious 
Adverse Events.

All deaths, regardless of cause, will be reported as an SAE

Non-bleeding, adverse events leading to permanent study drug discontinuation

Any SAE(s) that is not an endpoint event as listed above

Common types of adverse reactions to drug therapy, including but not limited to the 
following, when severe in intensity, should be considered SAEs:
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
46
Approved, Date: 16 June 2015

Suspected toxic effect on the bone marrow including severe thrombocytopenia (platelet 
count less than 50,000/µL), severe neutropenia (white blood cell count less than 
500 µL), pancytopenia, aplastic anemia

Suspected hypersensitivity reaction (eg, anaphylaxis, angioedema, severe urticaria, 
bronchospasm, etc.)

Severe skin reactions such as Stevens-Johnson Syndrome

Suspected severe liver injury
For all studies with an outpatient phase, including open-label studies, the subject must be 
provided with a "wallet (study) card" and instructed to carry this card with them for the duration 
of the study indicating the following:

Study number

Statement, in the local language(s), that the subject is participating in a clinical study

Investigator's name and 24-hour contact telephone number

Local sponsor's name and 24-hour contact telephone number (for medical staff only)

Site number

Subject number
The sponsor will provide the site with these study cards
12.3.2.
Serious Adverse Events
All serious adverse events occurring during the study must be reported to the appropriate sponsor 
contact person by study-site personnel within 24 hours of their knowledge of the event.
Information regarding serious adverse events will be transmitted to the sponsor using the Serious 
Adverse Event Form, which must be completed and signed by a physician from the study site, 
and transmitted to the sponsor within 24 hours. The initial and follow-up reports of a serious 
adverse event should be made by facsimile (fax).
All serious adverse events that have not resolved by the end of the study, or that have not 
resolved upon discontinuation of the subject's participation in the study, must be followed until 
any of the following occurs:

The event resolves

The event stabilizes

The event returns to baseline, if a baseline value/status is available

The event can be attributed to agents other than the study drug or to factors unrelated to 
study conduct

It becomes unlikely that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow-up after demonstration 
of due diligence with follow-up efforts)
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
47
Approved, Date: 16 June 2015
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospitalization (or prolongation of hospitalization) 
that occurs during the course of a subject's participation in a study must be reported as a serious 
adverse event, except hospitalizations for the following:

The
standard-of-care group
in this study will
involve a hospital admission for 
anticoagulation therapy to treat the PE. This hospital admission for patients randomized to 
the standard-of-care group should not be reported as an SAE. However, if, during the course 
of the hospital stay, a patient in the standard-of-care group develops a reportable event or 
has an event that prolongs the hospital stay beyond the expected duration, that event should 
be reported as an SAE. 

All inpatient hospitalizations for patients randomized to the rivaroxaban/early discharge arm 
and subsequent hospitalizations for patients randomized to the standard-of-care group 
should be reported as an SAE.

For the purposes of this study, endpoint events will not be considered SAEs, refer to 
Section 12.3.1 for details.

Hospitalizations not intended to treat an acute illness or adverse event (eg, social reasons 
such as pending placement in long-term care facility)

Surgery or procedure planned before entry into the study (must be documented in the 
eCRF). Note: Hospitalizations that were planned before the signing of the ICF, and where 
the underlying condition for which the hospitalization was planned has not worsened, will 
not be considered serious adverse events. Any adverse event that results in a prolongation of 
the originally planned hospitalization is to be reported as a new serious adverse event.
Any death of a subject that was not due to a study endpoint within 30 days of the last dose of 
study drug, whether or not the event is expected or associated with the study drug, is considered 
a serious adverse event.
12.3.3.
Pregnancy 
All initial reports of pregnancy in female subjects or partners of male subjects must be reported 
to the sponsor by the study-site personnel within 24 hours of their knowledge of the event using 
the appropriate pregnancy notification form. Abnormal pregnancy outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered serious 
adverse events and must be reported using the Serious Adverse Event Form. Any subject who 
becomes pregnant during the study must discontinue further study treatment. 
Follow-up information regarding the outcome of the pregnancy and any postnatal sequelae in the 
infant will be required
12.4.
Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safety issues or questions regarding the study are listed on the Contact Information 
page(s), which will be provided as a separate document.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
48
Approved, Date: 16 June 2015
13.
PRODUCT QUALITY COMPLAINT HANDLING
A product quality complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity, quality, 
durability, or reliability of a product, including its labeling or package integrity. A PQC may have 
an impact on the safety and efficacy of the product. Timely, accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor, and are mandated by regulatory agencies worldwide. The sponsor has 
established procedures in conformity with regulatory requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
13.1.
Procedures
All initial PQCs must be reported to the sponsor by the study-site personnel within 24 hours after 
being made aware of the event.
If the defect is combined with a serious adverse event, the study-site personnel must report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2, Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by the sponsor.
13.2.
Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality issues are listed on the Contact Information page(s), which will be 
provided as a separate document.
14.
STUDY DRUG INFORMATION
14.1.
Physical Description of Study Drug(s)
The rivaroxaban supplied for this study consists of 15 and 20 mg tablets. The 15 mg tablets are 
red, and the 20 mg tablets are dark red. It will be manufactured and provided under the 
responsibility of the sponsor. Refer to the Investigator's Brochure for a list of excipients.
14.2.
Packaging
The rivaroxaban study drug will be packaged in polypropylene blisters (the 15 and 20 mg starter 
pack dispensed at Randomization) and polyethylene bottles (the 20 mg tablets dispensed at 
Visit 2); both are dispensed in child-resistant packaging.
14.3.
Labeling
Study drug labels will contain information to meet the applicable regulatory requirements.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
49
Approved, Date: 16 June 2015
14.4.
Preparation, Handling, and Storage
For rivaroxaban tablets, no storage restrictions (temperature, humidity, light) apply. The storage 
recommendation for rivaroxaban is room temperature (approximately 15°C to 30°C) 
Refer to the pharmacy manual/study site investigational product manual for additional guidance on 
study drug preparation, handling, and storage.
14.5.
Drug Accountability
The investigator is responsible for ensuring that all study drug received at the site is inventoried 
and accounted for throughout the study. The dispensing of study drug to the subject, and the 
return of study drug from the subject, must be documented on the drug accountability form. 
Subjects must be instructed to return all original containers, whether empty or containing study 
drug. 
Study drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study site in a limited-access area or in a locked cabinet under appropriate 
environmental conditions. Unused study drug, and study drug returned by the subject, must be 
available for verification by the sponsor's study site monitor during on-site monitoring visits. The 
return to the sponsor of unused study drug, or used returned study drug for destruction, will be 
documented on the drug return form. When the study site is an authorized destruction unit and 
study drug supplies are destroyed on-site, this must also be documented on the drug return form.
Study drug should be dispensed under the supervision of the investigator or a qualified member 
of the study-site personnel, or by a hospital/clinic pharmacist. Study drug will be supplied only 
to subjects participating in the study. Returned study drug must not be dispensed again, even to 
the same subject. Whenever a subject brings his or her study drug to the study site for pill count, 
this is not seen as a return of supplies. Study drug may not be relabeled or reassigned for use by 
other subjects. The investigator agrees neither to dispense the study drug from, nor store it at, 
any site other than the study sites agreed upon with the sponsor.
15.
STUDY-SPECIFIC MATERIALS
The investigator will be provided with the following supplies:

Investigator's Brochure

Pharmacy manual/study site investigational product manual

Patient-reported outcome questionnaires and user manual-for the ACTS questionnaire only. 
Refer to   Attachment 3 and Attachment 4 for the PRO questionnaires. 

Interactive web response system manual

Sample ICF
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
50
Approved, Date: 16 June 2015
16.
ETHICAL ASPECTS
16.1.
Study-Specific Design Considerations
Potential subjects will be fully informed of the risks and requirements of the study and, during the 
study, subjects will be given any new information that may affect their decision to continue 
participation. They will be told that their consent to participate in the study is voluntary and may be 
withdrawn at any time with no reason given and without penalty or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential adverse events of the study, and provide their consent voluntarily will be enrolled.
The total blood volume to be collected is considered to be 6 ml. Subjects who agree to the optional 
biomarker sample will have an additional 10 mL drawn for a total blood volume of 16 mL.
16.2.
Regulatory Ethics Compliance
16.2.1.
Investigator Responsibilities
The investigator is responsible for ensuring that the study is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory and 
country-specific requirements.
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety, and well-being of 
study subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the study data are credible.
16.2.2.
Independent Ethics Committee or Institutional Review Board
Before the start of the study, the investigator (or sponsor where required) will provide the 
Independent Ethics Committee (IEC) or Institutional Review Board (IRB) with current and 
complete copies of the following documents (as required by local regulations):

Final protocol and, if applicable, amendments

Sponsor-approved ICF (and any other written materials to be provided to the subjects)

Investigator's Brochure (or equivalent information) and amendments/addenda

Sponsor-approved subject recruiting materials

Information on compensation for study-related injuries or payment to subjects for 
participation in the study, if applicable

Investigator's curriculum vitae or equivalent information (unless not required, as 
documented by the IEC/IRB)

Information regarding funding, name of the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjects

Any other documents that the IEC/IRB requests to fulfill its obligation
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
51
Approved, Date: 16 June 2015
This study will be undertaken only after the IEC/IRB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct), the ICF, applicable recruiting materials, and 
subject compensation programs, and the sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly identify the IEC/IRB and the documents being 
approved.
During the study the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:

Protocol amendments (excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct)

Revision(s) to ICF and any other written materials to be provided to subjects

If applicable, new or revised subject recruiting materials approved by the sponsor

Revisions to compensation for study-related injuries or payment to subjects for participation 
in the study, if applicable

New edition(s) of the Investigator's Brochure and amendments/addenda

Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB
(at least annually)

Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study drug

New information that may adversely affect the safety of the subjects or the conduct of the 
study

Deviations from or changes to the protocol to eliminate immediate hazards to the subjects

Report of deaths of subjects under the investigator's care

Notification if a new investigator is responsible for the study at the site

Development Safety Update Report and Line Listings, where applicable

Any other requirements of the IEC/IRB
For all protocol amendments (excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct), the amendment and applicable ICF revisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/IRB will be asked to review and reapprove this study. The 
reapproval should be documented in writing (excluding the ones that are purely administrative, 
with no consequences for subjects, data, or study conduct).
At the end of the study, the investigator (or sponsor where required) will notify the IEC/IRB 
about the study completion (if applicable, the notification will be submitted through the head of 
investigational institution).
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
52
Approved, Date: 16 June 2015
16.2.3.
Informed Consent
Each subject must give written consent according to local requirements after the nature of the 
study has been fully explained. The ICFs must be signed before performance of any 
study-related activity. The ICFs that are used must be approved by both the sponsor and by the 
reviewing IEC/IRB and be in a language that the subject can read and understand. The informed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulatory requirements, and sponsor policy.
Before enrollment in the study, the investigator or an authorized member of the study-site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study, and any discomfort participation in the study may entail. 
Subjects will be informed that their participation is voluntary and that they may withdraw 
consent to participate at any time. They will be informed that choosing not to participate will not 
affect the care the subject will receive for the treatment of his or her disease. Subjects will be told 
that alternative treatments are available if they refuse to take part and that such refusal will not 
prejudice future treatment. Finally, they will be told that the investigator will maintain a subject 
identification register for the purposes of long-term follow up if needed and that their records 
may be accessed by health authorities and authorized sponsor personnel without violating the 
confidentiality of the subject, to the extent permitted by the applicable law(s) or regulations. By 
signing the ICF the subject is authorizing such access, including permission to obtain 
information about his or her survival status, and agrees to allow his or her study physician to 
recontact the subject for the purpose of obtaining consent for additional safety evaluations, if 
needed, and subsequent disease-related treatments, or to obtain information about his or her 
survival status.
The subject will be given sufficient time to read the ICF and the opportunity to ask questions. 
After this explanation and before entry into the study, consent should be appropriately recorded 
by means of the subject's personally dated signature. After having obtained the consent, a copy of 
the ICF must be given to the subject.
16.2.4.
Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to fulfill the objectives of the study.
These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identity of subjects confidential.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
53
Approved, Date: 16 June 2015
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator/institution to allow direct access to his or her original 
medical records (source data/documents) for study-related monitoring, audit, IEC/IRB review, 
and regulatory inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study, and the applicable laws and regulations.
Exploratory biomarker research is not conducted under standards appropriate for the return of 
data to subjects. In addition, the sponsor cannot make decisions as to the significance of any 
findings resulting from exploratory research. Therefore, exploratory research data will not be 
returned to subjects or investigators, unless required by law or local regulations. Privacy and 
confidentiality of data generated in the future on stored samples will be protected by the same 
standards applicable to all other clinical data.
16.2.5.
Long-Term Retention of Samples for Additional Future Research 
Biomarker samples collected in this study may be stored for up to 10 years (or according to local 
regulations) for additional research. Samples will only be used to understand how rivaroxaban, 
impacts the anticoagulant disease state in patients with acute pulmonary embolism, analysis of 
molecules involved in the clotting process and the impact of concomitant medications used to 
treat PE. The research may begin at any time during the study or the post-study storage period. 
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer to Section 10.2, Withdrawal From the Study (Withdrawal From the Use 
of Samples in Future Research).
17.
ADMINISTRATIVE REQUIREMENTS
17.1.
Regulatory Documentation
17.1.1.
Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory authorities 
in each respective country, if applicable. A study may not be initiated until all local regulatory 
requirements are met.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
54
Approved, Date: 16 June 2015
17.1.2.
Required Prestudy Documentation
The following documents must be provided to the sponsor before shipment of study drug to the 
study site:

Protocol and amendment(s), if any, signed and dated by the principal investigator

A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if
applicable, subject compensation programs. This approval must clearly identify the specific 
protocol by title and number and must be signed (or sealed, where appropriate per local 
regulations) by the chairman or authorized designee.

Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, 
from the IEC/IRB, a general statement may be substituted for this list. If an investigator or a 
member of the study-site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the
vote/opinion of the study.

Regulatory authority approval or notification, if applicable

Signed and dated statement of investigator (eg, Form FDA 1572), if applicable

Documentation of investigator qualifications (eg, curriculum vitae)

Completed investigator financial disclosure form from the principal investigator, where 
required

Signed and dated clinical trial agreement, which includes the financial agreement

Any other documentation required by local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:

Completed investigator financial disclosure forms from all subinvestigators

Documentation of subinvestigator qualifications (eg, curriculum vitae)

Name and address of any local laboratory conducting tests for the study, and a dated copy of 
current laboratory normal ranges for these tests, if applicable

Local 
laboratory 
documentation 
demonstrating 
competence 
and 
test 
reliability 
(eg, accreditation/license), if applicable
17.2.
Protocol Amendments
Neither the investigator nor the sponsor will modify this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by the sponsor, and signed and dated by 
the investigator. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly submitted to the IEC/IRB and relevant competent authority.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
55
Approved, Date: 16 June 2015
Documentation of amendment approval by the investigator and IEC/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study, the 
IRB (and IEC where required) only needs to be notified.
During the course of the study, in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative (see Contact Information page(s) provided separately). Except in emergency 
situations, this contact should be made before implementing any departure from the protocol. In 
all cases, contact with the sponsor must be made as soon as possible to discuss the situation and 
agree on an appropriate course of action. The data recorded in the eCRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
17.3.
Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study. This document will be reviewed by the 
sponsor study-site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study file. To ensure subject confidentiality, no copy will be made. All 
reports and communications relating to the study will identify subjects by subject identification
and date of birth. In cases where the subject is not randomized into the study, the date seen and 
date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility for inclusion in the study.
17.4.
Source Documentation
At a minimum, source documentation must be available for the following to confirm data 
collected in the eCRF: subject identification, and study identification; study discussion and date 
of signed informed consent; dates of visits; results of safety and efficacy parameters as required 
by the protocol; record of all required adverse events and follow-up of adverse events; 
concomitant medication; drug receipt/dispensing/return records; study drug administration 
information; and date of study completion and reason for early discontinuation of study drug or 
withdrawal from the study, if applicable. 
In addition, the author of an entry in the source documents should be identifiable.
At a minimum, the type and level of detail of source data available for a subject should be 
consistent with that commonly recorded at the study site as a basis for standard medical care. 
Specific details required as source data for the study will be reviewed with the investigator 
before the study and will be described in the monitoring guidelines (or other equivalent 
document).
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
56
Approved, Date: 16 June 2015
The following data will be recorded directly into the eCRF and will be considered source data: 

Demographics, including race

Temperature, respiratory rate, pulse/heart rate and blood pressure

Height and weight 

Patient responses to the 2 PROs conducted by telephone
The minimum source documentation requirements for Section 4.1, Inclusion Criteria and 
Section 4.2, Exclusion Criteria that specify a need for documented medical history are as 
follows:

PE confirmation

CrCl and troponin results conducted at screening
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by subject interview or other protocol required assessment (eg, physical examination, 
laboratory assessment) and documented in the source documents.
17.5.
Case Report Form Completion
Case report forms are provided for each subject in electronic format.
Electronic Data Capture (eDC) will be used for this study. The study data will be transcribed by 
study-site personnel from the source documents onto an eCRF, and transmitted in a secure 
manner to the sponsor within the timeframe agreed upon between the sponsor and the study site. 
The electronic file will be considered to be the eCRF.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source documentation. All data relating to the 
study must be recorded in eCRFs prepared by the sponsor. Data must be entered into eCRFs in 
English. Study site personnel must complete the eCRF as soon as possible after a subject visit, 
and the forms should be available for review at the next scheduled monitoring visit.
All subjective measurements (eg, PRO) will be completed by the same individual who made the 
initial baseline determinations whenever possible. The investigator must verify that all data 
entries in the eCRFs are accurate and correct.
All eCRF entries, corrections, and alterations must be made by the investigator or other 
authorized study-site personnel. If necessary, queries will be generated in the eDC tool.
If corrections to a eCRF are needed after the initial entry into the eCRF, this can be done in 
3 different ways:
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
57
Approved, Date: 16 June 2015

Study site personnel can make corrections in the eDC tool at their own initiative or as a 
response to an auto query (generated by the eDC tool).

Study site manager can generate a query for resolution by the study-site personnel.

Clinical data manager can generate a query for resolution by the study-site personnel.
17.6.
Data Quality Assurance/Quality Control
Steps to be taken to ensure the accuracy and reliability of data include the selection of qualified 
investigators and appropriate study sites, review of protocol procedures with the investigator and 
study-site personnel before the study, and periodic monitoring visits by the sponsor. Written 
instructions will be provided for collection, handling, storage, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study-site personnel before 
the start of the study.
The sponsor will review eCRFs for accuracy and completeness during on-site monitoring visits 
and after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study database they will be verified for 
accuracy and consistency with the data sources. 
17.7.
Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRFs 
and all source documents that support the data collected from each subject, as well as all study 
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study documents as specified by the applicable regulatory requirement(s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by the applicable regulatory requirements or by an 
agreement with the sponsor. It is the responsibility of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will 
accept the responsibility. The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investigator relocate or dispose of any study 
documents before having obtained written approval from the sponsor.
If it becomes necessary for the sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the investigator/institution must permit access to such 
reports.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
58
Approved, Date: 16 June 2015
17.8.
Monitoring
The sponsor will use on site monitoring for this study.
The sponsor will perform on-site monitoring visits as frequently as necessary. The monitor will 
record dates of the visits in a study site visit log that will be kept at the study site. The first 
post-initiation visit will be made as soon as possible after enrollment has begun. At these visits, 
the monitor will compare the data entered into the eCRFs with the hospital or clinic records 
(source documents). The nature and location of all source documents will be identified to ensure 
that all sources of original data required to complete the eCRF are known to the sponsor and 
study-site personnel and are accessible for verification by the sponsor study-site contact. If 
electronic records are maintained at the study site, the method of verification must be discussed 
with the study-site personnel. 
Direct access to source documentation (medical records) must be allowed for the purpose of 
verifying that the data recorded in the eCRF are consistent with the original source data. Findings 
from this review of eCRFs and source documents will be discussed with the study-site personnel. 
The sponsor expects that, during monitoring visits, the relevant study-site personnel will be 
available, the source documentation will be accessible, and a suitable environment will be 
provided for review of study-related documents. The monitor will meet with the investigator on a 
regular basis during the study to provide feedback on the study conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during 
these remote contacts, study-site personnel will be available to provide an update on the progress 
of the study at the site. 
17.9.
Study Completion/Termination
17.9.1.
Study Completion
The study is considered completed with the last visit for the last subject participating in the 
study. The final data from the study site will be sent to the sponsor (or designee) after completion 
of the final subject visit at that study site, in the time frame specified in the Clinical Trial 
Agreement.
17.9.2.
Study Termination
The sponsor reserves the right to close the study site or terminate the study at any time for any 
reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A
study site is considered closed when all required documents and study supplies have been 
collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to:
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
59
Approved, Date: 16 June 2015

Failure of the investigator to comply with the protocol, the requirements of the IEC/IRB or 
local health authorities, the sponsor's procedures, or GCP guidelines

Inadequate recruitment of subjects by the investigator

Discontinuation of further study drug development
17.10. On-Site Audits
Representatives of the sponsor's clinical quality assurance department may visit the study site at 
any time during or after completion of the study to conduct an audit of the study in compliance 
with regulatory guidelines and company policy. These audits will require access to all study 
records, including source documents, for inspection and comparison with the eCRFs. Subject 
privacy must, however, be respected. The investigator and study-site personnel are responsible 
for being present and available for consultation during routinely scheduled study-site audit visits 
conducted by the sponsor or its designees. 
Similar auditing procedures may also be conducted by agents of any regulatory body, either as 
part of a national GCP compliance program or to review the results of this study in support of a 
regulatory submission. The investigator should immediately notify the sponsor if he or she has
been contacted by a regulatory agency concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding rivaroxaban or the sponsor's 
operations (eg, patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor to the investigator and not 
previously published, and any data, including biomarker research data, generated as a result of 
this study, are considered confidential and remain the sole property of the sponsor. The 
investigator agrees to maintain this information in confidence and use this information only to 
accomplish this study, and will not use it for other purposes without the sponsor's prior written 
consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of rivaroxaban, and thus may be disclosed 
as required to other clinical investigators or regulatory agencies. To permit the information 
derived from the clinical studies to be used, the investigator is obligated to provide the sponsor 
with all data obtained in the study.
The results of the study will be reported in a Clinical Study Report generated by the sponsor and 
will contain eCRF data from all study sites that participated in the study into the sponsor's 
database. Results of biomarker analyses performed after the Clinical Study Report has been 
issued will be reported in a separate report and will not require a revision of the Clinical Study 
Report. Study subject identifiers will not be used in publication of results. Any work created in 
connection with performance of the study and contained in the data that can benefit from 
copyright protection (except any publication by the investigator as provided for below) shall be 
the property of the sponsor as author and owner of copyright in such work.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
60
Approved, Date: 16 June 2015
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study site-specific data after the primary data are published. If an investigator wishes to publish 
information from the study, a copy of the manuscript must be provided to the sponsor for review 
at least 60 days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in 
writing, the investigator will withhold such publication for up to an additional 60 days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity or 
regulatory compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. For multicenter study designs and substudy approaches, secondary results generally 
should not be published before the primary endpoints of a study have been published. Similarly, 
investigators will recognize the integrity of a multicenter study by not submitting for publication 
data derived from the individual study site until the combined results from the completed study
have been submitted for publication, within 12 months of the availability of the final data (tables, 
listings, graphs), or the sponsor confirms there will be no multicenter study publication. 
Authorship of publications resulting from this study will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a significant 
contribution to the design of the study or analysis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required by law.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
61
Approved, Date: 16 June 2015
REFERENCES
1.
Aujesky D, Mazzolai L, Hugli O et al. Outpatient treatment of pulmonary embolism. Swiss Med Wkly 2009; 
139(47-48):685-690.
2.
Aujesky D, Perrier A, Roy PM, et al. Validation of a clinical prognostic model to identify low-risk patients 
with pulmonary embolism. J Intern Med. Jun 2007;261(6):597-604.
3.
Aujesky D, Roy PM, Le Manach CP, et al. Validation of a model to predict adverse outcomes in patients with 
pulmonary embolism. Eur Heart J. Feb 2006;27(4):476-481.
4.
Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute 
pulmonary embolism: an international, open-label, randomized, non-inferiority trial. Lancet. 2011; 378: 41–48.
5.
Bamber L, Wang MY, Prins MH, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus 
standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 2013; 110: 
732–741.
6.
Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS et al. Oral rivaroxaban for 
symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510.
7.
Beckman MG, Hooper WC, Critchley SE and Ortel TL. Venous Thromboembolism: A Public Health Concern.  
Am J Prev Med. 2010;38(4S)S495–S501.
8.
Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the 
treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297.
9.
Centers for Disease Control and Prevention. DVT/PE Data and Statistics. CDC.gov. Last update March 2015.
10.
Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE 
events and associated morbidity and mortality. Thromb Haemost. 2007;98:756-764.
11.
Corwin P, Toop L, McGeoch G, Than M, Wynn-Thomas S,Wells JE, et al.  Randomised controlled trial of 
intravenous antibiotic treatment for cellulitis at home compared with hospital. BMJ. 2005;330(7483):129.
12.
Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism 
after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001 Jul 7;358(9275):9-
15.
13.
Gibson J, Chambers CK, Venkatesh A.K et al. Prevalence and Patient Predictors of Outpatient Treatment of 
Venous Thromboembolic Disease. Ann Emerg Med (abstract). 2013;62(4):S36
14.
Investigator's Brochure: JNJ-39039039; Bay 59-7939 (rivaroxaban) Edition 22. Bayer HealthCare AG (31 
October 2014).
15.
Kabrhel C, Okechukwu I, Hariharan P, et al. Factors associated with clinical deterioration shortly after PE. 
Thorax. 2014;69(9):835-842
16.
Kahn SR, Lim W, Dunn AS, et al; American College of Chest Physicians. Prevention of VTE in nonsurgical 
patients: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians 
Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2):e195S-e226S.
17.
Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute 
major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997;30:1165–1171.
18.
Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in 
U.S. hospitals, 2002. Public Health Rep. 2007; 122:160-166.
19.
Kline JA, Yealy DM. Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE. 
Nature reviews. Cardiology. 2012;9(7):378-380.
20.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini 
JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. 
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91.
21.
Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after 
pulmonary embolism. N Engl J Med. 2004;350:2257-2264.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
62
Approved, Date: 16 June 2015
22.
Piran S, Le Gal G and Wells PS et al.  Outpatient treatment of symptomatic pulmonary embolism: A 
systematic review and meta-analysis Thromb Res. 2013; 132(5): 515-519.
23.
Prins MH, Bamber L and Cano SJ et al. Patient-reported treatment satisfaction with oral rivaroxaban versus 
standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial, Thromb Res 
(2014).  
24.
Singer AJ and Thode HC.  Low-risk pulmonary embolism in the ED.  Acad Emerg Med 2015;22(S1):S111.
25.
Spencer FA, Goldberg RJ, Lessard D, et al. Factors associated with adverse outcomes in outpatients presenting 
with pulmonary embolism: the Worcester Venous Thromboembolism Study. Circ Cardiovasc Qual 
Outcomes2010;3:390–394
26.
Stavros V. Konstantinides, Adam Torbicki, Giancarlo Agnelli, et al. 2014 ESC guidelines on the diagnosis and 
management of acute pulmonary embolism. Eur Heart J. 2014;35:3033–3073. Corrigendum to: 2014 ESC 
guidelines on the diagnosis and management of acute pulmonary embolism. Published 20 April 2015. 
27.
Stein PD, Beemath A, Olson RE. Trends in the incidence of pulmonary embolism and deep venous thrombosis 
in hospitalized patients. Am J Cardiol. 2005;95:1525-1526.
28.
Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R; CDC; Healthcare Infection Control Practices 
Advisory Committee. Guidelines for preventing health-care associated pneumonia, 2003: recommendations of 
CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004; 
53(RR-3):1-36.
29.
Torbicki A, Perrier A, Konstantinides S et al. Guidelines on the diagnosis and management of acute pulmonary 
embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European 
Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276–315.
30.
Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, et al. Rivaroxaban for the 
prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb 
Haemost. 2011; 105(3):444-453.
31.
Weitz JI, Linkins LA. Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opin 
Investig Drugs. 2007;16:271-282. 
32.
White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107 (23 Suppl 1):I4-8
33.
Zondag W, Kooiman J, Klok FA, Dekkers OM, Huisman MV. Outpatient versus inpatient treatment in patients 
with pulmonary embolism: a meta-analysis. Eur Respir J. Jul 2013;42(1):134-144.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
63
Approved, Date: 16 June 2015
Attachment 1
Reporting of Study Endpoints, Adverse Drug Reactions, Adverse Events and Serious Adverse Events
Study Endpoint
Study drug Adverse Drug Reactions 
(ADRs) and AEs leading to permanent 
study drug discontinuance
Other Serious Adverse Eventsa
Any Other Adverse Events
Recurrent PE or new or 
recurrent DVT or VTE 
related death
Bleeding events that:
Require medical 
attention, and/or 
hospitalization and 
any bleeding event 
leading to permanent 
study drug 
discontinuation
ISTH major bleeding 
events
Clinically relevant non-
major bleeding eventsb
Common types of adverse reactions to 
drug therapy, including but not limited to 
the following events:
Suspected toxic effect on the bone 
marrow including severe 
thrombocytopenia (platelet count less 
than 50,000/µL), severe neutropenia 
(white blood cell count less than 500 µL), 
pancytopenia, aplastic anemia
Suspected hypersensitivity reaction (eg, 
anaphylaxis, angioedema, severe 
urticaria, bronchospasm, etc.)
Severe skin reactions such as Stevens-
Johnson Syndrome
Suspected severe liver injury
Non-bleeding AEs leading to permanent 
drug discontinuation
Any event meeting the SAE 
criteria that is not a study endpoint
All deaths should be reported as an 
SAE
Any nonserious adverse event(s), of particular 
concern to the investigator
Capture in 
eCRF?
Yes 
Yes 
Yes
Captured if the investigator would like to notify 
the sponsor of the event
Capture as a 
SAE and 
report to 
Sponsor 
Safety Unit 
within 24 
hours?b
No
Does it meet the criteria as a SAE?
Yesa
Does it meet the criteria as a SAE?
Yes
No
Noc
No
a
Within 24 hours of the investigational staff’s knowledge of the event, the site should enter initial information in the eCRF regarding the event. Additional information should be 
recorded in the eCRF as soon as it becomes available.
b
All bleeding events will be AEs of Special Interest.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
64
Approved, Date: 16 June 2015
Attachment 2
Switching to or From Rivaroxaban 
PREMATURE DISCONTINUATION OF XARELTO
INCREASES THE RISK OF 
THROMBOTIC EVENTS. Premature discontinuation of any oral anticoagulant, including 
XARELTO, increases the risk of thrombotic events. To reduce this risk, consider coverage with 
another anticoagulant if XARELTO is discontinued for a reason other than pathological bleeding 
or completion of a course of therapy.
In order to provide guidance on switching to or from rivaroxaban the following guidance from 
the prescribing information is provided:
VKA to Rivaroxaban
When switching patients from warfarin to rivaroxaban, discontinue warfarin and start 
rivaroxaban as soon as the INR is below 3.0 to avoid periods of inadequate anticoagulation.
Rivaroxaban to VKA
No clinical trial data are available to guide converting patients from rivaroxaban to warfarin. 
Rivaroxaban affects INR, so INR measurements made during co-administration with warfarin 
may not be useful for determining the appropriate dose of warfarin. One approach is to 
discontinue rivaroxaban and begin both a parenteral anticoagulant and warfarin at the time the 
next dose of rivaroxaban would have been taken.
Non-Warfarin Anticoagulant to Rivaroxaban
For patients currently receiving an anticoagulant other than warfarin, start rivaroxaban 0 to 
2 hours prior to the next scheduled evening administration of the drug (low-molecular-weight 
heparin or non-warfarin oral anticoagulant) and omit the next regularly scheduled administration 
of the other anticoagulant. For unfractionated heparin being administered by continuous infusion, 
stop the infusion and start rivaroxaban at the same time.
Rivaroxaban to Non-Warfarin Anticoagulant
For patients currently taking rivaroxaban and transitioning to an anticoagulant with rapid onset, 
discontinue rivaroxaban and give the first dose of the other anticoagulant (oral or parenteral) at 
the time that the next rivaroxaban dose would have been taken.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
65
Approved, Date: 16 June 2015
Attachment 3
Anti-Clot Treatment Scale (ACTS) Questionnaire 
We are interested in your experiences of anti-clot treatment.  We would be grateful if you could 
help us by filling out this questionnaire.  The questions below ask about your experiences of anti-
clot treatment during the past 4 weeks.  All of the information you provide is COMPLETELY 
CONFIDENTIAL.  Please be sure to answer all questions.
INSTRUCTIONS:  We are interested in your experiences of anti-clot treatment during the past 
4 weeks.  Please circle the number in the box that best describes your views.
During the past 4 weeks...
Not at all
A little
Moderately
Quite a bit
Extremel
y
How much does the possibility of bleeding as a 
result of your anti-clot treatment limit you from 
taking part in vigorous physical activities (e.g. 
exercise, sports, dancing, etc.)?
1
2
3
4
5
How much does the possibility of bleeding as a 
result of your anti-clot treatment limit you from 
taking part in your usual activities (e.g. work, 
shopping, housework etc.)?
1
2
3
4
5
How bothered are you by the possibility of 
bruising as a result of your anti-clot treatment?
1
2
3
4
5
How bothered are you by having to avoid other 
medicines (e.g. aspirin) as a result of your anti-
clot treatment?
1
2
3
4
5
How much does your anti-clot treatment limit 
what you eat and drink (including alcohol)?
1
2
3
4
5
6.  How much of a hassle (inconvenience) are the 
daily aspects of your anti-clot treatment (e.g. 
remembering to take your medicine at a certain 
time, taking the correct dose of your medicine, 
limiting what you eat and drink (including 
alcohol), etc.)?
1
2
3
4
5
7.  How much of a hassle (inconvenience) are the 
occasional aspects of your anti-clot treatment
(e.g. the need for blood tests, going to or 
contacting the hospital/doctor, making 
arrangements for treatment while travelling etc.)?
1
2
3
4
5
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
66
Approved, Date: 16 June 2015
Now I want to ask you about daily and occasional aspects of your anti-clot treatment during the 
past 4 weeks…
Not at all
A little
Moderately
Quite a bit
Extremely
8.  How difficult is it to follow your anti-clot 
treatment?
1
2
3
4
5
9.  How time-consuming is your anti-clot 
treatment?
1
2
3
4
5
10. How much do you worry about your anti-clot 
treatment?
1
2
3
4
5
11. How frustrating is your anti-clot treatment?
1
2
3
4
5
12. How much of a burden is your anti-clot 
treatment?
1
2
3
4
5
13. Overall, how much of a negative impact has 
your anti-clot treatment had on your life?
1
2
3
4
5
14. How confident are you that your anti-clot 
treatment will protect your health (e.g. prevent 
blood clots, stroke, heart attack, DVT, 
embolism)?
1
2
3
4
5
15. How reassured do you feel because of your 
anti-clot treatment?
1
2
3
4
5
16. How satisfied are you with your anti-clot 
treatment?
1
2
3
4
5
17. Overall, how much of a positive impact has 
your anti-clot treatment had on your life?
1
2
3
4
5
THANK YOU FOR YOUR HELP
ACTS © Bayer AG, 2006. All Rights Reserved.
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
67
Approved, Date: 16 June 2015
Attachment 4
Site-of-Care Satisfaction Questionnaire
1. Overall how satisfied are you with the care you received?
Very Satisfied
Quite Satisfied
Neither
Quite Dissatisfied
Very Dissatisfied
2. Overall how satisfied are you with the location of care you received?
Very Satisfied
Quite Satisfied
Neither
Quite Dissatisfied
Very Dissatisfied
3. Do you think it is preferable to provide the kind of care you received?
In the Hospital
In the Community
No Preference
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
68
Approved, Date: 16 June 2015
Attachment 5
Cockcroft and Gault formulas
The creatinine clearance (expressed as mL/min), is yielded by the Cockcroft and Gault formulas, 
relating serum creatinine, with age (in years) and body weight (in kg). For this study, CrCl will 
be done by the local lab. The alternative formulas, based on µmol/L, are included below for your 
general reference only 
If one measures creatinine concentration in mg/dL, then the following 2 equations are used for 
men and women:
Men:
[(140 – age [yr]) weight (kg)]
     [72 creatinine (mg/dL)]
Women:
[(140 – age [yr]) weight (kg)]
0.85
     [72 creatinine (mg/dL)]
If one measures creatinine concentration in µmol/L, then the following 2 equations are used for 
men and women:
Men:
[(140 – age [yr]) weight (kg)]
  [0.814 creatinine (µmol/L)]
Women:
[(140 – age [yr]) weight (kg)]
0.85
[0.814 creatinine (µmol/L)]
NCT02584660


JNJ-39039039; BAY 59-7939 (rivaroxaban)
Clinical Protocol 39039039APE4001
69
Approved, Date: 16 June 2015
INVESTIGATOR AGREEMENT
I have read this protocol and agree that it contains all necessary details for carrying out this study. I will 
conduct the study as outlined herein and will complete the study within the time designated.
I will provide copies of the protocol and all pertinent information to all individuals responsible to me who 
assist in the conduct of this study. I will discuss this material with them to ensure that they are fully 
informed regarding the study drug, the conduct of the study, and the obligations of confidentiality.
Coordinating Investigator (where required):
Name (typed or printed):
Institution and Address:
Signature:
Date:
(Day Month Year)
Principal (Site) Investigator:
Name (typed or printed):
Institution and Address:
Telephone Number:
Signature:
Date:
(Day Month Year)
Note: If the address or telephone number of the investigator changes during the course of the study, written 
notification will be provided by the investigator to the sponsor, and a protocol amendment will not be required.
LAST PAGE
NCT02584660

SAP_001.pdf: 
1
Approved, Date: 27 April 2017
Janssen Scientific Affairs, LLC 
Statistical Analysis Plan
Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism from the 
Emergency Department
MERCURY PE 
Protocol 39039039APE4001; Phase 4
JNJ-39039039; BAY 59-7939  (rivaroxaban)
Status:
Approved
Date:
27 April 2017
Prepared by:
Janssen Research & Development, LLC  
Document No.: EDMS-ERI-142067631, 2.0
Compliance: The study described in this report was performed according to the principles of Good Clinical Practice (GCP). 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or 
confidential.
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
2
Approved, Date: 27 April 2017
TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
ABBREVIATIONS ........................................................................................................................................ 3
AMENDMENT HISTORY.............................................................................................................................. 4
1.
INTRODUCTION.................................................................................................................................. 5
1.1.
Trial Objectives ................................................................................................................................ 5
1.2.
Trial Design ...................................................................................................................................... 5
1.3.
Hypotheses for Trial Objectives ....................................................................................................... 6
1.4.
Sample Size Justification ................................................................................................................. 6
1.5.
Randomization and Blinding ............................................................................................................ 7
2.
ANALYSES PLANNED ....................................................................................................................... 7
2.1.
General Analysis Definitions ............................................................................................................ 7
2.1.1.
Visit Windows ............................................................................................................................... 7
2.1.2.
Pooling Algorithm for Analysis Centers ........................................................................................ 7
2.1.3.
Start and End of Study Periods .................................................................................................... 7
2.1.4.
Study Day ..................................................................................................................................... 7
2.1.5.
On Treatment................................................................................................................................ 8
2.2.
Analysis Sets.................................................................................................................................... 8
2.2.1.
ITT Analysis Set............................................................................................................................ 8
2.2.2.
Safety Analysis Set....................................................................................................................... 8
2.2.3.
Pharmacokinetics Analysis Set .................................................................................................... 8
2.2.4.
Definition of Subgroup .................................................................................................................. 8
2.3.
Methods of Analysis......................................................................................................................... 8
2.3.1.
Hypotheses for Analyses.............................................................................................................. 8
2.3.2.
Demographics and Baseline Characteristics................................................................................ 9
2.3.3.
Discontinuation/Completion Information....................................................................................... 9
2.3.4.
Extent of Exposure ....................................................................................................................... 9
2.3.5.
Protocol Deviations....................................................................................................................... 9
2.3.6.
Previous Medications.................................................................................................................... 9
2.3.7.
Concomitant Medications ........................................................................................................... 10
2.3.8.
Concomitant Medications Start during the Trial.......................................................................... 10
2.3.9.
Analysis for Primary Endpoint .................................................................................................... 10
2.3.9.1.
Primary Endpoint ..................................................................................................................... 10
2.3.9.2.
Analysis for Primary Endpoint ................................................................................................. 10
2.3.10.
Analyses for Secondary Endpoints............................................................................................. 10
2.3.10.1.
Secondary Endpoints .............................................................................................................. 10
2.3.10.2.
Analyses for Secondary Endpoints ......................................................................................... 11
2.3.11.
Analyses for Safety Endpoints.................................................................................................... 11
2.3.11.1.
Safety Endpoints ..................................................................................................................... 11
2.3.11.2.
Analyses for Adverse Events................................................................................................... 12
2.3.12.
Patient-Reported Outcomes ....................................................................................................... 12
2.3.13.
Medical Resource Utilization and Health Economics................................................................. 13
2.3.14.
Time to Onset of Events ............................................................................................................. 13
2.3.15.
Subgroup Analyses..................................................................................................................... 13
2.3.16.
Clinical Laboratory Tests ............................................................................................................ 14
2.3.17.
Vital Signs................................................................................................................................... 14
2.3.18.
Electrocardiogram....................................................................................................................... 14
2.4.
Interim Analysis.............................................................................................................................. 14
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
3
Approved, Date: 27 April 2017
ABBREVIATIONS
AE
ACTS
Adverse Event
Anti-Clot Treatment Scale
CEC
Clinical Endpoints Committee
CI
Confidence Interval
CRF
Case Report Form
CSR
Clinical Study Report
DMC
DVT
Data Monitoring Committee
Deep Vein Thrombosis
ECG
ED
Electrocardiogram
Emergency Department
eCRF
EOS
Electronic Case Report Form
End of Study/early withdrawal
ISTH
International Society on Thrombosis& Haemostasis
ICH
INR
International Conference on Harmonization
International Normalized Ratio
ITT
Intention-to-Treat
IWRS
Interactive Voice Response System
LOS
MPD
Length of Stay
Major Protocol Deviation
PE
PRO
Pulmonary Embolism
Patient Report Outcome
SAE
Serious Adverse Event
SAP
Statistical Analysis Plan
SD
TEAE
TESAE
VTE
Standard Deviation
Treatment Emergent Adverse Event
Treatment Emergent Serious Adverse Event
Venous Thromboembolism
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
4
Approved, Date: 27 April 2017
AMENDMENT HISTORY
SAP (VERSION 2.0) 
The original Statistical Analysis Plan (first version) was finalized and issued on 27 January 2016.  
All changes and clarifications of planned analyses in the SAP Version 2.0 (since the original 
SAP was issued) are listed below:
Topic or Section 
Description of Changes and Clarifications of Planned Analyses 
2.3.4. Extent of 
Exposure
The following paragraph
The drug compliance (%) for subjects randomized to receive 
rivaroxaban is calculated using the following formula

Drug compliance (%) = 100 x (number of pills dispensed – number 
of pills returned) /treatment duration.     
was replace by
Subjects who randomized to rivaroxaban take an initial dose of 15 mg 
orally twice daily for the first 21 days. The drug compliance (%) for 
this period is calculated using the following formula 

100 x (number of tablets taken during 15 mg BID part divided by 
2) / (date of the last study drug administration of 15 mg BID part -
date of the first study drug administration+1).
After first 21 days, subjects who randomized to rivaroxaban take dose 
of 20 mg orally once daily. The drug compliance (%) for this period is 
calculated using the following formula 

100 x (number of tablets taken during 20 mg QD part) / (date of 
the last study drug administration - date of the first study drug 
administration of 20 mg QD+1).
The overall drug compliance (%) is calculated using the following 
formula

100 x (number of tablets taken during 15 mg BID part divided by 2 
+ number of tablets taken during 20 mg QD part) / (date of the last 
study drug administration -
date of the first study drug 
administration+1).
2.3.10
Analyses for 
Secondary Endpoints
Deleted analyses at Day 3.
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
5
Approved, Date: 27 April 2017
1.
INTRODUCTION
This statistical analysis plan (SAP) contains definitions of analysis populations, derived variables 
and statistical analysis methods. 
1.1.
Trial Objectives
Primary Objective
The primary objective of the study is to demonstrate that low risk PE patients who are discharged 
from the ED to the home environment and treated with rivaroxaban as outpatients have fewer 
total days in the hospital for bleeding and/or venous thromboembolism (VTE) events through 
Day 30 compared to patients who are treated with initial hospitalization and standard-of-care.
Secondary Objective
The secondary objective of the study is to assess the reoccurrence of symptomatic, objectively 
confirmed VTE, defined as recurrent PE or new or recurrent DVT (including symptomatic upper 
extremity DVT) or VTE related death within 90 days of randomization. 
Exploratory Objective
The exploratory objective of this study is to evaluate patient outcomes by baseline risk factors
1.2.
Trial Design
This is a randomized, open-label, parallel-group, multicenter study conducted in the United 
States (US). Eligible subjects will include men and women, 18 years of age and older, who have 
a confirmed diagnosis of acute symptomatic PE with or without symptomatic DVT. 
Approximately 300 PE subjects presenting to the ED and assessed as being at low risk of clinical 
deterioration using the Hestia criteria will be randomized in a 1:1 ratio to one of two treatment 
strategies: 1) rivaroxaban and discharge from the ED to the home environment or 2) standard-of-
care (as per local protocol and defined by the medical team caring for the subject). All subjects 
will be followed for 90 days after starting randomized treatment. Subjects meeting all inclusion 
and no exclusion criteria will be eligible for enrollment.
The study consists of a Screening and Randomization Period, followed by a 90-day open-label 
treatment period, and an end-of-study/early withdrawal (EOS) visit. The duration of study
participation for each subject is approximately 3 months.
Subjects will undergo screening in the ED and must be randomized within 12 hours after the 
confirmation of PE diagnosis. All bleeding events (ISTH major and clinically relevant non-major 
bleeding events), efficacy events (VTE related death, recurrence of PE or new or recurrent DVT) 
and all deaths during the study will be adjudicated in a blinded manner by a Clinical Endpoints 
Committee (CEC). Events will be adjudicated throughout the entire 90 days of randomized 
treatment. The CEC will independently review clinical events data as they become available, and 
will adjudicate and will classify deaths, bleeding events, and recurrence of PE and new or 
recurrent DVT in a consistent and unbiased manner.
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
6
Approved, Date: 27 April 2017
An independent Data Monitoring Committee (DMC) will monitor the progress of the study and 
will ensure the safety of study subjects. An Executive Committee will review recommendations 
from the DMC regarding safety analyses and/or study modifications and will oversee 
implementation, if necessary, of these study modifications. In addition a Study Coordinator 
Operational Committee will provide input to the operational logistics regarding study design and 
conduct of the study.
The frequency and timing of efficacy, safety, and other measurements are provided in Time and 
Events Schedule in the study protocol.
1.3.
Hypotheses for Trial Objectives
Clinical:
The clinical hypothesis is that an early discharge strategy for low risk PE patients, identified in 
the ED, and discharged to the home environment and treated with rivaroxaban as outpatients will 
result in fewer days in the hospital for bleeding and/or VTE events through Day 30 than patients 
treated with standard-of-care.
Safety:
The safety hypothesis is that major bleeding rates as assessed by the International Society on 
Thrombosis and Haemostasis (ISTH) criteria at 90 days of randomized treatment will be similar 
between the rivaroxaban and standard-of-care strategies.
1.4.
Sample Size Justification
Following pragmatic considerations, the sample size for this study was determined using 
assumptions related to the expected number of days of initial inpatient hospitalization (beginning 
from randomization to discharge from the hospital) and any subsequent hospitalization(s) related 
to bleeding and/or VTE events up to 30 days. A large-sample confidence interval (CI) approach 
was used to determine the sample size required for estimating the difference in mean length of 
stay between the two randomized groups.  From Aujesky et al. 2011 (see protocol for details); 
the standard deviation is 1 day for the outpatient group and 3.1 days for the inpatient group from 
the initial hospital stay. From the available data, the average number of days of hospitalization 
after discharge is less than 2 days and the percentage of patients with VTE related hospitalization 
is less than 5%. With this information, the contribution from VTE related hospitalization after 
discharge has a very small impact on the standard deviations received from the initial hospital 
stays which were used in the sample size calculation. A total of a 150 subjects per group will 
provide a two-sided 95% CI with about a 0.5 day of margin of error. The margin of error is 
defined as the quantity from the observed difference in means to the end point of the CI.
The above sample size estimate will also allow an examination of the difference in the 
recurrence of VTE events in the 2 randomized groups. The incidence of recurrent VTE events is 
generally low and largely infrequent among low-risk PE patients. In the Aujesky et al. 2011 
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
7
Approved, Date: 27 April 2017
study, the 90-day recurrence rates of VTE among both inpatients and outpatients were reported 
to be less than 1% (with a 95% upper confidence limit = 2.7%).
1.5.
Randomization and Blinding
The principle purpose of randomization is to ensure unbiased treatment assignment in a manner 
that assures minimum allocation bias, and balancing both known and unknown prognostic 
factors at the baseline. Subjects will be randomly assigned in a 1:1 ratio to the outpatient group 
to receive rivaroxaban or to the inpatient group to receive standard-of-care. The treatment 
assignment is based on a computer-generated randomization schedule prepared before the study 
by or under the supervision of the sponsor. The randomization will be balanced by using 
randomly permuted blocks and will be stratified by study centers. As this is an open label study, 
blinding procedures are not applicable.
2.
ANALYSES PLANNED
2.1.
General Analysis Definitions
2.1.1.
Visit Windows
Two study periods are defined as follows:

Randomization to visit two

Visit two to the end of study
Data collected from different study periods are analyzed accordingly.  
2.1.2.
Pooling Algorithm for Analysis Centers
Small centers may be pooled if the analyses are stratified by centers.  
2.1.3.
Start and End of Study Periods
The trial termination date will be the completion date of the entire trial. The trial reference start 
date/time for a subject will be the date/time of randomization of the subject. The trial reference 
end date for a subject is the date of the last trial-related procedure for the subject and is defined 
as the maximum of

Date of last visit (scheduled or unscheduled visit; Early Study

Medication Discontinuation Visit/End of Study Visit)

Date of the last study medication
2.1.4.
Study Day
When needed, the following definitions of Study Day can be used. For each subject, each day 
during the trial will be assigned a Study Day with respect to the trial reference start date which is
the date of randomization of the subject.
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
8
Approved, Date: 27 April 2017

Study Day = Assessment date – trial reference start date + 1; if assessment date ≥trial 
reference start date

Study Day = Assessment date - trial reference start date; if assessment date < trial reference 
start date. 
2.1.5.
On Treatment
A study subject is considered to be on treatment during the period from the first study medication 
administration (instead of randomization) to the Minimum (Earliest) of [Trial end date/time, 
Date/time of Death, Date/time of the last study medication administration + 2 days], which is 
defined as the end of being on-treatment. A safety endpoint event or safety abnormality (of 
clinical laboratory or vital signs) is considered to occur while on treatment if its onset date/time
(complete or missing/incomplete) is logically possible to be within the on treatment period.
2.2.
Analysis Sets
For the purpose of statistical analyses, 2 analysis sets will be considered:

Intention-to-treat (ITT) analysis set: The intention to treat analysis set includes randomized
subjects who meet trial enrollment criteria.  Screen Failure patients who were randomized in 
error are not included in ITT.

Safety analysis set: The safety population includes all randomized subjects who take at least
1 dose of study drug.
2.2.1.
ITT Analysis Set
All analyses, except safety analyses, are based on the intention-to-treat (ITT) analysis set for this 
study.  
2.2.2.
Safety Analysis Set
Any safety measures will be summarized using safety population.
2.2.3.
Pharmacokinetics Analysis Set
No PK data will be collected for this study.
2.2.4.
Definition of Subgroup
Centers may be considered as subgroups.  
2.3.
Methods of Analysis
2.3.1.
Hypotheses for Analyses
For detailed clinical and safety hypotheses, see Section 1.3.
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
9
Approved, Date: 27 April 2017
2.3.2.
Demographics and Baseline Characteristics
Descriptive statistics (such as mean, standard deviation, median, minimum and maximum) by 
treatment group will be provided for continuous variables such as age, weight, and height. 
Counts and (appropriate) percentages by treatment group will be provided for categorical 
variables such as sex and race.
2.3.3.
Discontinuation/Completion Information
Incidences and percentages of discontinuations from the study in different study periods will be 
provided by treatment group. Time to discontinuation may be summarized by treatment group 
using the Kaplan-Meier method depending on the rate of discontinuation.
Subjects who 
complete the study will be censored at the time of the end of study.
2.3.4.
Extent of Exposure
The following treatment duration will be calculated:

Treatment duration (including days off study drug) = Date of the last study medication 
administration - date of the first study medication administration + 1
Subjects who randomized to rivaroxaban take an initial dose of 15 mg orally twice daily for the 
first 21 days. The drug compliance (%) for this period is calculated using the following formula 

100 x (number of tablets taken during 15 mg BID part divided by 2) / (date of the last study 
drug administration of 15 mg BID part - date of the first study drug administration+1).
After first 21 days, subjects who randomized to rivaroxaban take dose of 20 mg orally once 
daily. The drug compliance (%) for this period is calculated using the following formula 

100 x (number of tablets taken during 20 mg QD part) / (date of the last study drug 
administration - date of the first study drug administration of 20 mg QD+1).
The overall drug compliance (%) is calculated using the following formula

100 x (number of tablets taken during 15 mg BID part divided by 2 + number of tablets 
taken during 20 mg QD part) / (date of the last study drug administration - date of the first 
study drug administration+1).
2.3.5.
Protocol Deviations
Major protocol deviations (MPD) will be summarized (or provided by a listing if the number of 
MPD is too small) by treatments. Definitions of major protocol deviations based on data reviews 
will be provided in this study SAP, and will be finalized before the database lock.
2.3.6.
Previous Medications
For the safety population, the number and percentage of subjects who receive medications prior 
to first study medication administration will be summarized. A concomitant medication record is 
considered as previous medication if
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
10
Approved, Date: 27 April 2017

The earliest logically possible start date of the medication < date of first study medication 
administration.
2.3.7.
Concomitant Medications
For the safety population, the number and percentage of subjects who receive concomitant 
medications during the treatment period (between the first and last study medication 
administrations) will be summarized. A medication record will be considered concomitant 
medication during the treatment if both of the following conditions are met:

The earliest logically possible start date of the medication ≤date of the last study medication 
administration

The latest logically possible stop date of the medication ≥ date of the first study medication 
administration, or stop date of the medication is “continuing”.
2.3.8.
Concomitant Medications Start during the Trial
A concomitant medication record will be considered concomitant medication started during the 
treatment if:

The earliest logically possible start date of the concomitant medication > date of the earliest 
study medication administration, and < date of the last study medication administration.
2.3.9.
Analysis for Primary Endpoint
The primary analysis will be based on ITT analysis set. All statistical tests will be based on the 
0.05 alpha level of significance (2-sided). No adjustments in the Type 1 error for multiplicity 
will be made.
2.3.9.1.
Primary Endpoint
The primary clinical endpoint is the number of days of initial inpatient hospitalization (beginning
from randomization to discharge from the hospital) plus any subsequent hospitalization(s) related
to bleeding and/or VTE events up to 30 days.
2.3.9.2.
Analysis for Primary Endpoint
The primary endpoint will be calculated for each subject.  A two-sided 95% CI will be calculated 
for the mean difference of length of stay (LOS) in hospital from 2 treatment groups. No testing 
for the primary hypothesis will be performed.
2.3.10.
Analyses for Secondary Endpoints
The secondary analyses will be based on ITT analysis set.
2.3.10.1.
Secondary Endpoints
The following secondary endpoints will be analyzed 
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
11
Approved, Date: 27 April 2017

Reoccurrence of symptomatic objectively confirmed VTE, defined as recurrent PE or new or 
recurrent DVT (including symptomatic upper extremity DVT) or VTE related death within
7,14,30 and 90 days of randomization.

Number of unplanned hospital or physician office visits for VTE symptoms and/or bleeding
through 90 days.

Length of initial and subsequent hospitalization(s) for any reason through Day 90.
2.3.10.2.
Analyses for Secondary Endpoints
All secondary endpoints will be summarized.
A right-sided 95% CI will be calculated, using EXACT method (for example, a procedure
similar to StatXact 9 with exact option), for the difference (the proportion of rivaroxaban minus 
the proportion of standard care) of event rates of reoccurrence of symptomatic, objectively 
confirmed VTE, defined as recurrent PE or new or recurrent DVT (including symptomatic upper 
extremity DVT) or VTE related death within 90 days of randomization. The same procedure 
may be applied to the reoccurrence of VTE at Day  7, 14 and Day 30 when appropriate.
A two-sided 95% CI, based on large sample normal approximation, will be calculated for the 
difference of the rates of unplanned hospital or physician office visits for VTE symptoms and/or 
bleeding through 90 days.
Under the assumption of normal distribution, a two-sided 95% CI will be calculated for the 
difference in length of initial and subsequent hospitalization(s) for any reason through Day 90.
2.3.11.
Analyses for Safety Endpoints
The secondary analyses will be based on safety analysis set.
2.3.11.1.
Safety Endpoints
The primary safety endpoint is ISTH major bleeding at Day 90; these events will be adjudicated 
by CEC.  The secondary safety endpoints include:

VTE related death within 90 days of randomization

Clinically relevant non-major bleeding

Minimal bleeding

Overall safety defined as a composite of ISTH major bleeding, clinically relevant non-major 
bleeding, and mortality.
Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for 
major bleeding but associated with medical intervention, unscheduled contact (visit or telephone 
call) with a physician (temporary) cessation of study treatment, or associated with discomfort for 
the subject such as pain or impairment of activities of daily life.
Minimal bleeding is defined as all other overt bleeding episodes that do not meet the ISTH
criteria for major or clinically relevant non-major bleeding.
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
12
Approved, Date: 27 April 2017
All safety endpoints will be summarized or listed by treatment groups. The 95% CI for the 
difference of event rates between treatments may be provided when appropriate.
2.3.11.2.
Analyses for Adverse Events
The original terms used in the CRFs by investigators to identify AE will be coded using the 
Medical Dictionary for Regulatory Activities (MedDRA).
Treatment Emergent Adverse Event
Treatment emergent adverse event (TEAE) is defined as an adverse event starting between the 
first study medication administration and 2 days after the last study medication administration 
during the treatment period, or an event that starts before the first study medication but it is 
worsening during above mentioned period.
Specific Definition
A TEAE flag will be created in the analysis dataset as specified below:

When the onset date is complete:
The AE will be flagged as TEAE if the onset date ≥ the date of the first study medication 
administration AND ≤2 days after the last study medication administration

When the onset date of the AE is incomplete/missing:
The TEAE will be determined on a case-by-case basis.
Duration of Adverse Event
For the computations of duration in days of a TEAE or duration in days of an AE, the following 
approach will be used (which is based on date but not time):

Duration of AE = Latest logically possible AE resolution date – earliest logically possible 
AE onset date + 1.
Summaries of Adverse Events
Unless stated otherwise, all summaries of adverse events (AE) will be provided by system organ 
class and dictionary-derived (preferred) term. A total column will be included in all safety 
summaries. The number and percentage of subjects with TEAEs and Treatment-emergent 
Serious Adverse Events (TESAE) will be summarized for each treatment group by system organ 
class and dictionary-derived term. Event rates of TEAEs and TESAEs will also be provided.
All AEs are coded using MedDRA, Version 15.1.
2.3.12.
Patient-Reported Outcomes
Anti-Clot Treatment Scale (ACTS)
At follow-up visits Day 14, Day 30, and Day 90, treatment satisfaction will be assessed using a 
validated measure for treatment satisfaction: the Anti-Clot Treatment Scale (ACTS). It includes a 
12-item (items 1 to 12) ACTS Burdens scale and a 3-item (items 14 to 16) ACTS Benefits scale.
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
13
Approved, Date: 27 April 2017
The item 13 is the assessment for overall burden, and the item 17 is the assessment for overall 
benefit. The scores range from ‘Not at all’ to ‘Extremely’ on a five-point Likert scale 
(psychometric rating). 
All items will be summarized by treatment arms. Items 13 and 17 will be compared between 
treatment groups assuming the averages of the scores are approximated normally distributed. 
Site-of-Care Satisfaction Questionnaire
The Satisfaction to Site-of-Care questionnaire (standard-of-care versus early discharge on 
rivaroxaban therapy) will be administered after 7 days on anticoagulant therapy (See Attachment 
4 of the protocol).
Satisfaction to Site-of-Care (hospitalization versus home care) rates the patient’s level of 
satisfaction to care and location with care received as well as preference to location of care 
provided. Patients rate  2 items of this scale of 1=Very satisfied; 2=Quite satisfied; 3=Neither; 
4=Quite dissatisfied; and 5=Very dissatisfied for satisfaction questions and for the one 
preference question responses include 1=In the hospital; 2=In the community; and 3=No 
preference.
All items will be summarized.  The first two items will be compared between treatment groups 
assuming the averages of the scores are approximately normally distributed.
2.3.13.
Medical Resource Utilization and Health Economics
Medical resource utilization and health economics data, associated with medical encounters, will 
be collected in the eCRF for all subjects throughout the study. Length of initial and subsequent 
hospitalizations as well as, all-cause and VTE related re-hospitalizations due to recurrence will 
be economically evaluated.
2.3.14.
Time to Onset of Events
Time to onset of an event may be calculated. The events of interest may include major bleeding 
and first VTE related re-hospitalizations. The distributions of time to onset of event observed 
from the 2 treatment groups will be estimated using the Kaplan Meier method. However, if the 
number of events is too small, a listing will be provided without using the KM method.
Treatments will be compared using a log-rank test when appropriate (depending on the number 
of events).
2.3.15.
Subgroup Analyses
The only potential subgroups are study centers.  There is no subgroup analysis planned at this 
time. 
NCT02584660


JNJ-39039039; BAY 59-7939  (rivaroxaban)
Statistical Analysis Plan 39039039APE4001
14
Approved, Date: 27 April 2017
2.3.16.
Clinical Laboratory Tests
Descriptive statistics (mean, standard deviation, median, minimum and maximum) will be 
provided for each laboratory analyte at baseline. A clinical laboratory test value is considered 
abnormal if it is outside the reference range. 
2.3.17.
Vital Signs
Summaries by treatment group for the observations and changes from baseline to the last 
observation (excluding baseline) for the vital sign parameters will be provided.
2.3.18.
Electrocardiogram
Summaries by treatment group for the ECG parameters will be provided.
2.4.
Interim Analysis
There is no interim analysis planned for this study.
NCT02584660